[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4100
1. Wang Y, Fang M, Sun X, Sun J: Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival. Int J Lab Hematol; 2010 Apr;32(2):230-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival.
  • Bone marrow samples were collected from 148 patients with acute leukemia (AL).
  • Based on the stage of the disease, patients were divided into the newly diagnosed group, the relapsed group and the complete remission (CR) group. telomerase activity (TA) was examined by PCR-ELISA, and telomere length (TL) was examined by Southern blot analyses.
  • TA had no difference between acute nonlymphocytic leukemia (ANLL) group and acute lymphocytic leukemia (ALL) group.
  • [MeSH-major] Leukemia / metabolism. Leukemia / physiopathology. Telomerase / metabolism. Telomere / genetics
  • [MeSH-minor] Adult. Aged. Blotting, Southern. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Reference Standards

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614710.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


2. Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR: Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature. Leuk Lymphoma; 2006 Sep;47(9):1902-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients have ongoing complete clinical remissions with a median follow-up of 17, 19 and 39 months post achievement of complete remission.
  • One patient died at age 87 years from a non-related cause after 5.5 years of complete remission.
  • One patient received local radiotherapy to a solitary cutaneous site of large-cell lymphoma that developed after 3 years in remission from the low-grade CBCL; no recurrences of either grade CBCL have yet occurred.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Remission Induction. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065004.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 006927
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


3. Bassotti G, Villanacci V, Mazzocchi A, Castellani D, Giuliano V, Corsi S, Morelli A: Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission. Eur J Gastroenterol Hepatol; 2006 May;18(5):507-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission.
  • AIMS: To assess the colonic high-amplitude and low-amplitude propulsive activity and the colonic motor response to eating in patients with ulcerative colitis in remission.
  • PATIENTS AND METHODS: Fourteen patients were recruited, all with the disease in remission as documented by clinical and endoscopic criteria.
  • CONCLUSIONS: Colonic propulsive activity in ulcerative colitis in remission is almost normal, even though the low-amplitude propagated activity tends to be similar to that observed in patients with the irritable bowel syndrome, thus possibly contributing to the persistence of abdominal symptoms in a subgroup of patients.
  • [MeSH-minor] Adult. Defecation / physiology. Female. Humans. Male. Manometry / methods. Middle Aged. Muscle Contraction / physiology

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607145.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O'Reilly RJ: Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant; 2008 Apr;14(4):458-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.
  • From 1985 to 2004, 49 patients with advanced myelodysplastic syndromes (MDS) (> or =5% blasts) or acute myeloid leukemia (AML) transformed from MDS underwent T cell depleted bone marrow or peripheral blood hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings following conditioning with a myeloablative regimen that included total body irradiation (44 patients) or busulfan (5 patients).
  • Prior to transplantation, 22 of the 36 treated patients were in hematologic remission; 4 were in a second refractory cytopenia phase (26 responders); 8 had failed to achieve remission; and 2 of the responders had progression or relapse of their MDS (10 failures).
  • Only 3 patients developed acute GVHD (aGVHD) (grades I and III) and 1 chronic GVHD (cGVHD).
  • These results indicate that patients with advanced MDS who achieve and remain in remission or a second refractory cytopenia phase with chemotherapy before conditioning can achieve successful long-term remissions following a myeloablative T cell depleted allogeneic HSCT.
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Graft vs Host Disease / prevention & control. Humans. Middle Aged. Remission Induction. Retrospective Studies. Siblings. Transplantation Conditioning / methods. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342789.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023766; United States / NCI NIH HHS / CA / P30 CA008748; United States / NHLBI NIH HHS / HL / R01 HL088134
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Other-IDs] NLM/ NIHMS43830; NLM/ PMC4498391
  •  go-up   go-down


5. Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD, Mayo P2C Phase II Consortium: A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica; 2009 Oct;94(10):1375-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 study of vorinostat in acute myeloid leukemia.
  • SAHA) in patients with relapsed acute myeloid leukemia and in selected untreated patients with high-risk acute myeloid leukemia.
  • DESIGN AND METHODS: Patients with relapsed or untreated acute myeloid leukemia who were not candidates for chemotherapy entered one of the two treatment arms.
  • In arm A (n=15), the confirmed complete remission rate was 0% (95% CI, 0% to 23%); this arm was closed at the planned interim analysis.
  • In arm B (n=22), the confirmed complete remission rate was 4.5% (1 response; 95% CI, 0.4% to 24%), with a duration of response exceeding 398 days.
  • CONCLUSIONS: Vorinostat monotherapy demonstrated minimal activity in this group of patients with acute myeloid leukemia.
  • Future studies of vorinostat in acute myeloid leukemia should focus on combinations with other drugs with which it might interact pharmacodynamically.
  • [MeSH-major] Hydroxamic Acids / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2001;3(2):122-33 [11250759.001]
  • [Cites] Mol Med. 2000 Oct;6(10):849-66 [11126200.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8 [11535817.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1321-30 [11696577.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):287-97 [11703323.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8492-7 [11731433.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):194-202 [11902574.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):963-70 [11948101.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Dec;11(12):1695-713 [12457432.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3236-9 [12446442.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2118-26 [12727828.001]
  • [Cites] Blood. 2003 May 15;101(10):4055-62 [12531799.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4460-71 [12907619.001]
  • [Cites] Curr Med Chem. 2003 Nov;10(22):2343-50 [14529477.001]
  • [Cites] Cancer Biol Ther. 2003 Sep-Oct;2(5):544-51 [14614324.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2896-905 [18660379.001]
  • [Cites] Cancer. 2008 Oct 1;113(7 Suppl):1933-52 [18798533.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1698-707 [19223502.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2580-9 [15059915.001]
  • [Cites] Ann Med. 2004;36(4):304-14 [15224657.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5705-8 [8650156.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2841-51 [8874180.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):103-13 [9045296.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2978-86 [9376578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7 [9501205.001]
  • [Cites] Annu Rev Biochem. 1998;67:545-79 [9759497.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4116-24 [10361108.001]
  • [Cites] Nature. 1999 Sep 9;401(6749):188-93 [10490031.001]
  • [Cites] Expert Opin Ther Targets. 2005 Aug;9(4):809-24 [16083344.001]
  • [Cites] J Invest Dermatol. 2005 Nov;125(5):1045-52 [16297208.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1794-803 [16532500.001]
  • [Cites] Cancer J. 2007 Mar-Apr;13(2):80-3 [17476134.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1060-6 [17962510.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1886-93 [18591380.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):681-92 [10690554.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9 [10954755.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5165-70 [11016644.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2292-300 [11489804.001]
  • (PMID = 19794082.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00305773
  • [Grant] United States / NCI NIH HHS / CA / K24 CA111717; United States / NCI NIH HHS / CA / K24 CA111717-05; United States / NCI NIH HHS / CM / N01 CM17104
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  • [Other-IDs] NLM/ PMC2754953
  •  go-up   go-down


6. Tamori A, Enomoto M, Kobayashi S, Iwai S, Morikawa H, Sakaguchi H, Habu D, Shiomi S, Imanishi Y, Kawada N: Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat; 2010 Feb 1;17(2):123-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Combination therapy with ADV and LAM can maintain biochemical remission in patients with LAM-refractory HBV.
  • [MeSH-minor] Adult. Aged. Alanine Transaminase / blood. Creatinine / blood. DNA, Viral / blood. Fanconi Syndrome / chemically induced. Female. Humans. Lamivudine / pharmacology. Lamivudine / therapeutic use. Male. Middle Aged. Phosphates / blood. Serum / virology. Treatment Outcome. Viral Load

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Viral Hepat. 2011 Nov;18(11):820 [21054684.001]
  • (PMID = 19674281.001).
  • [ISSN] 1365-2893
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Organophosphonates; 0 / Phosphates; 2T8Q726O95 / Lamivudine; AYI8EX34EU / Creatinine; EC 2.6.1.2 / Alanine Transaminase; JAC85A2161 / Adenine; U6Q8Z01514 / adefovir dipivoxil
  •  go-up   go-down


7. Cesaro S, Pillon M, Visintin G, Putti MC, Gazzola MV, D'Amore E, Scarzello G, Zanesco L, Messina C, Rosolen A: Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series. Eur J Haematol; 2005 Jul;75(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After a follow-up of 11-42 months, all patients are alive in complete hematological and molecular remission; and three of them without any chronic GVHD.
  • [MeSH-minor] Adolescent. Adult. Antilymphocyte Serum / administration & dosage. Child. Child, Preschool. Cyclosporine / administration & dosage. Female. Follow-Up Studies. Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect / drug effects. Graft vs Leukemia Effect / radiation effects. Histocompatibility Testing. Humans. Male. Risk Factors. Secondary Prevention. Transplantation Conditioning. Transplantation, Homologous. Whole-Body Irradiation


8. Kemppainen T, Tammi R, Tammi M, Agren U, Julkunen R, Böhm J, Uusitupa M, Kosma VM: Elevated expression of hyaluronan and its CD44 receptor in the duodenal mucosa of coeliac patients. Histopathology; 2005 Jan;46(1):64-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: The study group consisted of 52 patients with coeliac disease in remission, 40 patients with newly diagnosed disease and 10 healthy control subjects.
  • The percentage of HA-positive cells in surface epithelium was higher in newly diagnosed patients (13%) compared with patients in remission (11%) and controls (2%).
  • In patients with active disease, 22-26% of the surface epithelium was CD44+, whereas the corresponding figure in patients in remission was 5%, and that of controls 1%.
  • CONCLUSIONS: The HA-positive coat on surface epithelium seen even in patients in remission suggests persistent or even permanent changes in the epithelial permeability barrier in coeliac disease.
  • [MeSH-minor] Adult. Antibodies, Monoclonal / metabolism. Biopsy. Case-Control Studies. Female. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Ki-67 Antigen / metabolism. Male. Remission, Spontaneous

  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15656888.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD44; 0 / Ki-67 Antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


9. Brouwer C, Vermunt-de Koning DG, Trueworthy RC, Ter Riet PG, Duley JA, Trijbels FJ, Hoogerbrugge PM, Bökkerink JP, van Wering ER, De Abreu RA: Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects. Pediatr Blood Cancer; 2006 Apr;46(4):434-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects.
  • IMPDH activities were determined in children who were diagnosed with and treated for acute lymphoblastic leukemia (ALL), and in a group of control children.
  • CONCLUSION: The decrease of IMPDH activity at remission of ALL seems to be at least partly due to the eradication of lymphoblasts with the type 2 isoform of the enzyme.
  • [MeSH-major] IMP Dehydrogenase / metabolism. Leukocytes, Mononuclear / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Enzyme Activation. Female. Humans. Infant. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16333815.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.205 / IMP Dehydrogenase
  •  go-up   go-down


10. Maksimowicz-McKinnon K, Clark TM, Hoffman GS: Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum; 2007 Mar;56(3):1000-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the clinical, laboratory, and radiographic manifestations of Takayasu arteritis (TA) in a cohort from the US, evaluate the response to interventions, remission and relapse rates, and disease progression, and compare these observations with those from other cohorts in the US, Japan, India, Italy, and Mexico.
  • Initial angiographic studies showed aortic abnormalities in 79% of patients and frequent involvement of the subclavian (65%) and carotid (43%) arteries.Ninety-three percent of longitudinally followed patients attained disease remission of any duration, but only 28% sustained remission of at least 6 months' duration after prednisone was tapered to <10 mg daily.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Coronary Restenosis / drug therapy. Coronary Restenosis / ethnology. Coronary Restenosis / prevention & control. Drug Therapy, Combination. Female. Humans. India / ethnology. Italy / ethnology. Japan / ethnology. Longitudinal Studies. Male. Mexico / ethnology. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome. United States / ethnology

  • Genetic Alliance. consumer health - Takayasu arteritis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17328078.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents
  •  go-up   go-down


11. Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kröger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeier U, Freund M: Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol; 2010 Jul 10;28(20):3344-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients in complete remission (CR; 42%) or non-CR (58%) received grafts from matched related (47%) or matched unrelated (51%) donors; one patient had a mismatched related donor (2%).
  • [MeSH-minor] Adolescent. Adult. Drug Therapy, Combination. Feasibility Studies. Female. Humans. Male. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. TREOSULFAN .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2010 Aug 10;28(23):3797
  • (PMID = 20498405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] CO61ER3EPI / treosulfan; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


12. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A: Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol; 2008 Dec;143(5):707-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In CEL with FIP1L1-PDGFRA (n = 16) or various PDGFRB fusion genes (n = 5), complete haematological remission (CHR) was achieved in 95% (20/21) after 3 months.
  • Complete molecular remission (CMR) was seen in 75% (12/16) of cases with FIP1L1-PDGFRA positive CEL by 6 months, and in 87% (13/15) after 12 months.
  • [MeSH-minor] Adult. Benzamides. Cytogenetics. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm, Residual. Oncogene Proteins, Fusion / genetics. Protein Kinase Inhibitors / therapeutic use. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor beta / genetics. Remission Induction / methods. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. mRNA Cleavage and Polyadenylation Factors / genetics

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Apr;145(1):132-4 [19120352.001]
  • (PMID = 18950453.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / FIP1L1-PDGFRA fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / mRNA Cleavage and Polyadenylation Factors; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


13. Cohen-Gadol AA, Wilhelmi BG, Collignon F, White JB, Britton JW, Cambier DM, Christianson TJ, Marsh WR, Meyer FB, Cascino GD: Long-term outcome of epilepsy surgery among 399 patients with nonlesional seizure foci including mesial temporal lobe sclerosis. J Neurosurg; 2006 Apr;104(4):513-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If a patient was in Class I at 1 year postoperatively, the probability of seizure remission at 10 years postoperatively was 92% (95% CI 89-96%); almost all seizures occurred during the 1st year after surgery.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Outcome Assessment (Health Care). Retrospective Studies

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619654.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, del Valle y Fuentes F, Götze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, Hensel M, Benner A, Zick L, Döhner K, Fröhling S, Döhner H, AML Study Group (AMLSG): High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia; 2005 Jun;19(6):978-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
  • The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL).
  • In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytarabine / administration & dosage. Idarubicin / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Mitoxantrone / administration & dosage. Tretinoin / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics. Remission Induction. fms-Like Tyrosine Kinase 3

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2005 Jun;19(6):913-5 [15843820.001]
  • (PMID = 15843821.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; BZ114NVM5P / Mitoxantrone; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; ZRP63D75JW / Idarubicin; AIDA protocol; MAC chemotherapy protocol
  •  go-up   go-down


15. Arafat AM, Möhlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schöfl C, Pfeiffer AF: Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab; 2008 Apr;93(4):1254-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using cutoff limits of 1 microg/liter (Immulite) and 0.5 microg/liter (Nichols) identified 95% of patients with active disease and 78-80% of patients in remission.
  • [MeSH-minor] Adult. Age Factors. Aged. Calibration. Female. Humans. Male. Middle Aged. Reference Values. Sex Factors


16. Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B: Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biol Blood Marrow Transplant; 2006 Jan;12(1):102-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.
  • Acute graft-versus-host disease (GVHD) was limited to grade I to II, whereas chronic graft-versus-host disease occurred in 9 patients, mostly (n = 7) with limited disease.
  • Molecular relapses (8 chronic myeloid leukemia [CML] and 1 non-Hodgkin lymphoma) that occurred not earlier than the sixth month after transplantation were treated with donor lymphocyte infusion (DLI), which induced complete remission in all but 1 CML patient with persistent very low BCR-ABL molecular levels.
  • [MeSH-major] Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect. Leukocyte Reduction Procedures. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm. Female. Hematopoietic Stem Cell Mobilization. Histocompatibility Testing. Humans. Lymphocyte Transfusion. Male. Middle Aged. Recurrence. Survival Analysis. T-Lymphocytes

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399574.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


17. Ferrá C, Sanz J, de la Cámara R, Sanz G, Bermúdez A, Valcárcel D, Rovira M, Serrano D, Caballero D, Espigado I, Morgades M, Heras I, Solano C, Duarte R, Barrenetxea C, García-Noblejas A, Díez-Martin JL, Iriondo A, Carreras E, Sierra J, Sanz MA, Ribera JM, GETH (Grupo Español de Trasplante Hematopoyético) and PETHEMA (Programa Español de Tratamiento en Hematología), Spanish Society of Hematology: Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source. Biol Blood Marrow Transplant; 2010 Jul;16(7):957-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
  • Adults with high-risk acute lymphoblastic leukemia (HR-ALL) have a poor outcome with standard chemotherapy and usually undergo unrelated stem cell transplantation (SCT) if a matched sibling donor is not available.
  • We analyzed the outcome of adult patients with unrelated SCT for HR-ALL and studied the possible effect of the hematopoietic stem cell source of the transplant.
  • A total of 149 adult patients (median age, 29 years, range, 15-59 years) with HR-ALL underwent unrelated SCT in 13 Spanish institutions between 2000 and 2007.
  • Patients in first complete remission (CR1) at transplantation had at least one adverse prognostic factor (advanced age, adverse cytogenetics, hyperleukocytosis, or slow response to induction therapy).
  • All unrelated transplantation modalities were associated with high treatment-related mortality for adult HR-ALL patients without a sibling donor.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Humans. Living Donors. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Survivors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20144909.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Oriuchi N, Higuchi T, Endo K, Tsukamoto N, Matsuda H, Kuji I, Murakami K, Nakajima K: [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients]. Kaku Igaku; 2009 Jun;46(2):96-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete remission on the PET (CR(PET)) was defined as the FDG uptake lower than the background and compared with the final response assessment.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Rituximab. Vinblastine / administration & dosage. Vincristine / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637820.001).
  • [ISSN] 0022-7854
  • [Journal-full-title] Kaku igaku. The Japanese journal of nuclear medicine
  • [ISO-abbreviation] Kaku Igaku
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; CHOP protocol
  •  go-up   go-down


19. Ramanarayanan J, Dunford LM, Baer MR, Sait SN, Lawrence W, McCarthy PL: Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients. Leuk Res; 2006 Jun;30(6):701-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
  • Recent improved treatments for lymphoid malignancies produce more long-term survivors, yet increase the risk for secondary malignancies.
  • Therapy-related myelodysplasia and acute myeloid leukemia are well described, but secondary chronic myeloid leukemia (CML) has only rarely been reported.
  • We report three patients with CML diagnosed 8, 10 and 2.5 years following Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia therapy, respectively.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Neoplasms, Second Primary / therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Remission Induction. Time Factors. Transplantation, Homologous


20. Chun JK, Schulman MR: The infected breast prosthesis after mastectomy reconstruction: successful salvage of nine implants in eight consecutive patients. Plast Reconstr Surg; 2007 Sep;120(3):581-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Remission Induction. Retrospective Studies


21. Mizuta S, Kohno A, Morishita Y, Atsuta Y, Sao H, Miyamura K, Sakamaki H, Ueda R, Morishima Y: Long-term follow-up of 14 patients with philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission. Int J Hematol; 2007 Feb;85(2):140-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of 14 patients with philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission.
  • We describe the clinical outcome of autologous bone marrow transplantation (ABMT) for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).
  • Between 1985 and 2000, 14 patients in first complete remission underwent transplantation.
  • In all cases, harvested marrow was purged with a cocktail of complement and monoclonal antibodies to common acute lymphoblastic leukemia antigen (CALLA).
  • For the 6 surviving patients in continuous remission, the median follow-up period was 96 months.
  • [MeSH-major] Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Recurrence. Remission Induction. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Dec;13(12):2053-8 [10602428.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Med Oncol. 1994;11(2):75-88 [7850267.001]
  • [Cites] Blood. 1992 Jun 1;79(11):3067-70 [1586748.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(9):731-5 [9384474.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Mar;9(3):206-12 [12652472.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):365-9 [8704688.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):623-32 [12692601.001]
  • [Cites] Jpn J Cancer Res. 1985 Dec;76(12):1222-9 [3937834.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(11):1029-33 [9877263.001]
  • [Cites] Bone Marrow Transplant. 1995 Nov;16(5):663-7 [8547863.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Oct;36(1):49-58 [10996522.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3507-12 [15315963.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Jpn J Cancer Res. 1985 Dec;76(12):1212-21 [3937833.001]
  • [Cites] Bone Marrow Transplant. 1993 Apr;11(4):255-9 [7683550.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2602-9 [9116308.001]
  • [Cites] Bone Marrow Transplant. 1999 Oct;24(7):777-84 [10516682.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(12):1217-22 [10414906.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(6):597-603 [11128809.001]
  • (PMID = 17321992.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Gassab L, Mechri A, Bacha M, Gaddour N, Gaha L: [Affective temperaments in the bipolar and unipolar disorders: distinctive profiles and relationship with clinical features]. Encephale; 2008 Oct;34(5):477-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were in remission of a major depressive episode.
  • [MeSH-minor] Adult. Affective Disorders, Psychotic / diagnosis. Affective Disorders, Psychotic / psychology. Cyclothymic Disorder / diagnosis. Cyclothymic Disorder / psychology. Female. Humans. Male. Middle Aged. Personality Inventory / statistics & numerical data. Psychometrics. Recurrence. Risk Factors. Seasonal Affective Disorder / diagnosis. Seasonal Affective Disorder / psychology

  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068336.001).
  • [ISSN] 0013-7006
  • [Journal-full-title] L'Encéphale
  • [ISO-abbreviation] Encephale
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Vogel MN, Weisel K, Maksimovic O, Peters S, Brodoefel H, Claussen CD, Horger MS: Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease. AJR Am J Roentgenol; 2009 Sep;193(3):656-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were found in 25 of 202 intervals (12.4%) of progressive disease, in 14 of 171 intervals (8.2%) of disease remission, and in 10 of 188 intervals (5.3%) of stable disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Chi-Square Distribution. Female. Humans. Incidence. Male. Middle Aged. Radiographic Image Interpretation, Computer-Assisted. Retrospective Studies

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696278.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  •  go-up   go-down


24. Gutiérrez A, Francés R, Amorós A, Zapater P, Garmendia M, Ndongo M, Caño R, Jover R, Such J, Pérez-Mateo M: Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. Inflamm Bowel Dis; 2009 Apr;15(4):508-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BactDNA translocation was present in 7 out of 21 (33%) and in 10 out of 15 (34%) patients with CD and UC in remission, respectively.
  • This fact is associated with a marked Th1-driven immune reaction in CD patients, even in those in remission.
  • [MeSH-minor] Adult. Female. Humans. Male. Microbiological Techniques. Middle Aged. Th1 Cells / immunology. Th1 Cells / microbiology. Th2 Cells / immunology. Th2 Cells / microbiology

  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058229.001).
  • [ISSN] 1536-4844
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA, Bacterial
  •  go-up   go-down


25. Yu CS, Kim TW, Kim JH, Choi WS, Kim HC, Chang HM, Ryu MH, Jang SJ, Ahn SD, Lee SW, Shin SS, Choi EK, Kim JC: Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys; 2007 Mar 15;67(4):1020-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Capecitabine. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Multivariate Analysis. Remission Induction. Retrospective Studies

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197127.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Vizjak A, Ferluga D, Rozic M, Hvala A, Lindic J, Levart TK, Jurcić V, Jennette JC: Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol; 2008 Nov;19(11):2237-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the patients with sufficient follow-up data, complete remission of the nephrotic syndrome occurred in 77% of those with a minimal change-like lesion, progression to end-stage renal disease occurred in 33% of those with FSGS, and renal disease remained stable in 57% of those with proliferative glomerulonephritis.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Glomerulonephritis, Membranoproliferative / immunology. Glomerulonephritis, Membranoproliferative / pathology. Glomerulosclerosis, Focal Segmental / immunology. Glomerulosclerosis, Focal Segmental / pathology. Humans. Male. Microscopy, Fluorescence. Middle Aged. Nephrosis, Lipoid / immunology. Nephrosis, Lipoid / pathology. Nephrotic Syndrome / immunology. Nephrotic Syndrome / pathology. Prognosis


27. Gupta A, Singh M, Singh H, Kumar L, Sharma A, Bakhshi S, Raina V, Thulkar S: Infections in acute myeloid leukemia: an analysis of 382 febrile episodes. Med Oncol; 2010 Dec;27(4):1037-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infections in acute myeloid leukemia: an analysis of 382 febrile episodes.
  • Neutropenic fever is an important cause of morbidity and mortality during therapy of acute myeloid leukemia (AML).
  • Between May, 2001 and December, 2006, 95 patients with de novo non-M3 AML received remission induction chemotherapy followed by consolidation in those who achieved complete remission.
  • [MeSH-major] Fever / etiology. Infection / etiology. Leukemia, Myeloid, Acute / complications. Neutropenia / etiology
  • [MeSH-minor] Adolescent. Adult. Anti-Bacterial Agents / therapeutic use. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2000 Jan;25(2):147-52 [10673672.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):730-51 [11850858.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2722-30 [9531581.001]
  • [Cites] Jpn J Antibiot. 1994 Sep;47(9):1196-201 [7990260.001]
  • [Cites] Ann Intern Med. 1984 Mar;100(3):345-51 [6696356.001]
  • [Cites] Jpn J Antibiot. 1992 Aug;45(8):1003-8 [1433888.001]
  • [Cites] Drugs. 1997 May;53(5):789-804 [9129866.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2150-9 [8683249.001]
  • [Cites] Blood. 1998 May 15;91(10):3607-15 [9572995.001]
  • [Cites] Eur J Haematol. 2008 Nov;81(5):354-63 [18637030.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4710-8 [9389686.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5684-8 [18955453.001]
  • [Cites] Support Care Cancer. 2008 Sep;16(9):1085-8 [18274787.001]
  • [Cites] Ann Oncol. 2003 May;14(5):795-801 [12702536.001]
  • [Cites] J Infect. 2006 Oct;53(4):266-73 [16388852.001]
  • [Cites] Hematol J. 2003;4(6):420-6 [14671614.001]
  • [Cites] Int J Antimicrob Agents. 2007 Nov;30 Suppl 1:S51-9 [17689933.001]
  • [Cites] Leukemia. 2004 Jan;18(1):72-7 [14586478.001]
  • [Cites] Jpn J Antibiot. 1993 Mar;46(3):251-8 [8510322.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1068-75 [16885047.001]
  • [Cites] Clin Infect Dis. 1996 Oct;23(4):795-805 [8909847.001]
  • [Cites] J Infect. 2007 Jun;54(6):567-71 [17188750.001]
  • [Cites] Infect Control Hosp Epidemiol. 1994 Feb;15(2):101-4 [8201230.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] Isr Med Assoc J. 2007 Jun;9(6):424-9 [17642387.001]
  • [Cites] Jpn J Antibiot. 1993 Oct;46(10):912-7 [8254893.001]
  • [Cites] Clin Infect Dis. 2001 Dec 1;33(11):1816-23 [11668430.001]
  • [Cites] Jpn J Antibiot. 1991 Sep;44(9):979-86 [1960859.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):567-77 [15274070.001]
  • [Cites] Med Oncol. 2000 May;17(2):111-6 [10871816.001]
  • [Cites] Eur J Haematol. 2007 Sep;79(3):226-33 [17655696.001]
  • [Cites] J Med Assoc Thai. 2005 Nov;88 Suppl 8:S124-34 [16858853.001]
  • [Cites] Pediatr Infect Dis J. 2008 Nov;27(11):974-80 [18833026.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1179-87 [9508206.001]
  • [Cites] Clin Infect Dis. 2003 May 1;36(9):1103-10 [12715303.001]
  • [Cites] J Hosp Infect. 2002 Aug;51(4):288-96 [12183144.001]
  • [Cites] J Assoc Physicians India. 1992 Jan;40(1):18-20 [1634456.001]
  • [Cites] Hematology. 2006 Oct;11(5):335-40 [17607583.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):228-37 [14716755.001]
  • (PMID = 19830601.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


28. Turrini O, Ychou M, Moureau-Zabotto L, Rouanet P, Giovannini M, Moutardier V, Azria D, Delpero JR, Viret F: Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol; 2010 Oct;36(10):987-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Tumor progression was documented in 11 patients (32%), stable disease was documented in 20 patients (59%), and partial remission was documented in 3 patients (9%).
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Confidence Intervals. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreatectomy / methods. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Adjuvant. Risk Assessment. Survival Analysis. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Ltd.
  • (PMID = 20828979.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


29. Liu J, Lu DP, Zhang Y: [The prognosis and cytogenetic characteristics of acute erythroid leukemia: a report of 55 cases]. Zhonghua Nei Ke Za Zhi; 2006 Sep;45(9):738-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The prognosis and cytogenetic characteristics of acute erythroid leukemia: a report of 55 cases].
  • OBJECTIVE: To explore the prognosis and cytogenetic characteristics of acute erythroid leukemia.
  • METHODS: We selected 55 patients with acute erythroid leukemia and reviewed the cytogenetic characteristics of these cases.
  • With case-control studies, 55 patients were classified as primary or MDS transformed leukemia depending on the absence or presence of MDS history.
  • In these patients, total complete remission rate was 63.6%.
  • Among them, the complete remission rate of acute erythroid leukemia with MDS history was lower than that without MDS history (42.8% vs 85.2%, P < 0.05).
  • The complete remission rate of acute erythroid leukemia with aberrant karyotypes was lower than that with normal karyotypes (37.0% vs 83.3%, P < 0.01).
  • CONCLUSIONS: Acute erythroid leukemia patients with aberrant karyotypes or MDS history are usually resistant to chemotherapy.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / diagnosis. Leukemia, Erythroblastic, Acute / genetics
  • [MeSH-minor] Adult. Chromosome Aberrations. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Karyotyping. Male. Prognosis. Retrospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166448.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Pajor A, Józefowicz-Korczyńska M: [Vestibular compensation in patients with vestibular neuronitis]. Otolaryngol Pol; 2006;60(5):747-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients were classified according to vestibular index scores in the first examination as acute--subacute stage--20 patients and compensation stage--10 patients; in the second examination--as remission stage--19 patients, and compensation stage--11 patients.
  • A comprison of vestibular index in each patient during follow-up revealed that 13 patients (43.3%) had presented dynamic recovery and changed acute--subacute stage to remission stage.
  • In others a recovery was slower, so 13 patients (43.3%) changed acute-subacute stage to compensation stage and 4 patients (13.3%) stayed all the time in compensation stage. CONCLUSIONS:.
  • [MeSH-minor] Adult. Female. Gait. Humans. Male. Middle Aged. Postural Balance. Sensitivity and Specificity. Severity of Illness Index. Vestibular Function Tests. Vestibular Nerve / physiopathology

  • MedlinePlus Health Information. consumer health - Dizziness and Vertigo.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263249.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


31. Koom WS, Seong J, Han KH, Lee DY, Lee JT: Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas? Int J Radiat Oncol Biol Phys; 2010 Aug 1;77(5):1433-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemoembolization, Therapeutic / methods. Combined Modality Therapy / methods. Female. Humans. Infusions, Intra-Arterial / methods. Male. Middle Aged. Radiotherapy Dosage. Remission Induction. Survival Rate. Tumor Burden

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19896779.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J: Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol; 2008 Jun;144(6):738-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In general, patients responded poorly to skin-directed therapy and in almost all cases required systemic agents to induce even a partial remission, including patients with early-stage disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Diterpenes. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Survival Rate


33. Piccaluga PP, Martinelli G, Rondoni M, Visani G, Baccarani M: Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. Expert Opin Biol Ther; 2006 Oct;6(10):1011-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia.
  • Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) is the most common subtype of ALL in adults.
  • Conventional chemotherapy-based approaches that are effective in other precursor B cell ALL cases have a poor chances of cure in patients with a Ph+ diagnosis.
  • Therefore, allogeneic stem cell transplantation performed during the first remission is the recommended therapy.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Philadelphia Chromosome
  • [MeSH-minor] Adult. Animals. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Randomized Controlled Trials as Topic / trends. Stem Cell Transplantation / methods. Stem Cell Transplantation / trends

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989583.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


34. Lewis M, Scott J, Frangou S: Impulsivity, personality and bipolar disorder. Eur Psychiatry; 2009 Oct;24(7):464-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However it is unclear whether increased impulsivity is also a trait feature of BD and therefore present in remission.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Psychometrics / statistics & numerical data. Reference Values. Regression Analysis. Statistics as Topic

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793639.001).
  • [ISSN] 0924-9338
  • [Journal-full-title] European psychiatry : the journal of the Association of European Psychiatrists
  • [ISO-abbreviation] Eur. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


35. Caballero D, García-Marco JA, Martino R, Mateos V, Ribera JM, Sarrá J, León A, Sanz G, de la Serna J, Cabrera R, González M, Sierra J, San Miguel J: Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res; 2005 Nov 1;11(21):7757-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
  • PURPOSE: To evaluate the efficacy of reduced intensity conditioning (RIC) allogeneic transplant in 30 patients with poor-prognosis chronic lymphocytic leukemia (CLL) and/or high-risk molecular/cytogenetic characteristics.
  • All six patients with 17p deletion were transplanted with active disease, including three with refractory disease; all except one reached complete remission after the transplant and two are alive and disease free.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 17 / genetics. Immunoglobulin Heavy Chains / chemistry. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Transplantation Conditioning / methods. Transplantation, Homologous / methods
  • [MeSH-minor] Adult. Aged. Antigens, CD19 / biosynthesis. Antigens, CD5 / biosynthesis. Antigens, CD79 / biosynthesis. DNA Mutational Analysis. Disease-Free Survival. Female. Flow Cytometry. Humans. Kinetics. Male. Middle Aged. Mutation. Prognosis. Proportional Hazards Models. Receptors, IgE / biosynthesis. Risk. Stem Cells / cytology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278397.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD5; 0 / Antigens, CD79; 0 / Immunoglobulin Heavy Chains; 0 / Receptors, IgE
  •  go-up   go-down


36. Lin JZ, Zeng ZF, Wu XJ, Wan DS, Chen G, Li LR, Lu ZH, Ding PR, Pan ZZ: Phase II study of pre-operative radiotherapy with capecitabine and oxaliplatin for rectal cancer and carcinoembryonic antigen as a predictor of pathological tumour response. J Int Med Res; 2010 Mar-Apr;38(2):645-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Capecitabine. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Preoperative Care. Prospective Studies. Radiotherapy Dosage. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515578.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Nishida Y, Saito Y, Yokota T, Kanda T, Mizusawa H: Skeletal muscle MRI in complex regional pain syndrome. Intern Med; 2009;48(4):209-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Conventional magnetic resonance imaging (MRI) sequences of patients with complex regional pain syndrome (CRPS) have shown abnormal signals in skin, soft tissue, joints, bone, and bone marrow, but not yet in skeletal muscles, during the acute phase.
  • The aim of this study was to clarify whether or not the affected muscles in CRPS patients show abnormal MRI signal intensities or signal enhancement by gadolinium dimeglumine during the acute phase.
  • Out of three patients, MRI was performed on three at stage 1, one in improving phase, two in remission phase, and one at stage 3.
  • CONCLUSION: MRI abnormalities in the acute phase are consistent with muscular edema, interstitial edema, and vascular hyperpermeability.
  • [MeSH-minor] Adult. Aged. Female. Gadolinium. Humans. Image Enhancement. Male. Microvessels / pathology. Young Adult


38. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med; 2005 Feb 3;352(5):441-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 57 patients who had a complete response, 40 remained in remission for 4.3 to 7.7 years.
  • [MeSH-minor] Adult. Aged. B-Lymphocytes. Bone Marrow Examination. Disease-Free Survival. Female. Gene Rearrangement / drug effects. Genes, bcl-2. Humans. Leukocyte Count. Male. Middle Aged. Radiometry. Remission Induction. Survival Analysis. Thyrotropin / blood

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2005 Feb 3;352(5):496-8 [15689589.001]
  • (PMID = 15689582.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00042; United States / NCI NIH HHS / CA / R01 CA56794
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / iodine-131 anti-B1 antibody; 9002-71-5 / Thyrotropin
  •  go-up   go-down


39. Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group: Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol; 2008 Nov;143(4):503-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
  • The clinical significance of minimal residual disease (MRD) is uncertain in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) treated with imatinib-combined chemotherapy.
  • Here we report the results of prospective MRD monitoring in 100 adult patients.
  • Ninety-seven patients (97%) achieved complete remission (CR), and the relapse-free survival (RFS) rate was 46% at 3 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Fusion Proteins, bcr-abl / analysis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Adolescent. Adult. Benzamides. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm, Residual. Piperazines / administration & dosage. Prognosis. Prospective Studies. Pyrimidines / administration & dosage. Recurrence. Reverse Transcriptase Polymerase Chain Reaction / methods. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Sep;146(5):576-7 [19555375.001]
  • (PMID = 18986386.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


40. Pulcini C, Couadau T, Bernard E, Lorthat-Jacob A, Bauer T, Cua E, Mondain V, Chichmanian RM, Dellamonica P, Roger PM: Adverse effects of parenteral antimicrobial therapy for chronic bone infections. Eur J Clin Microbiol Infect Dis; 2008 Dec;27(12):1227-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Remission was observed in 84 patients (65%).
  • [MeSH-minor] Adult. Aged. Female. Humans. Infusions, Intravenous / adverse effects. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Antimicrob Chemother. 2002 Jan;49(1):149-54 [11751779.001]
  • [Cites] Chemotherapy. 2001;47 Suppl 1:5-16 [11096184.001]
  • [Cites] J Antimicrob Chemother. 2004 Feb;53(2):127-9 [14688050.001]
  • [Cites] J Clin Pharm Ther. 2001 Dec;26(6):445-51 [11722682.001]
  • [Cites] Med Mal Infect. 2006 Mar;36(3):132-7 [16580802.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):684-92 [12424071.001]
  • [Cites] Pathol Biol (Paris). 2004 Dec;52(10):566-74 [15596304.001]
  • [Cites] Neth J Med. 2000 Dec;57(6):215-23 [11099790.001]
  • [Cites] Lancet. 2004 Jul 24-30;364(9431):369-79 [15276398.001]
  • [Cites] N Engl J Med. 2004 Oct 14;351(16):1645-54 [15483283.001]
  • [Cites] Int J Antimicrob Agents. 2004 Nov;24(5):473-8 [15519480.001]
  • [Cites] Am J Med. 1999 Jan;106(1):44-9 [10320116.001]
  • [Cites] Clin Infect Dis. 2004 Jun 15;38(12):1651-72 [15227610.001]
  • [Cites] Presse Med. 2003 Aug 23;32(27):1263-8 [14506448.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Dec;23(12):759-69 [12517020.001]
  • (PMID = 18818959.001).
  • [ISSN] 1435-4373
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


41. Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, Yee KW, Kamel-Reid S, Chang H, Lipton JH, Messner HA, Xu W, Brandwein JM: Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol; 2009 Jun;146(1):76-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.
  • Between 2000 and 2006, 85 adult BCR-ABL negative acute lymphoblastic leukaemia (ALL) patients between 18 and 60 years of age were treated using a modified paediatric regimen, which included high doses of asparaginase delivered weekly for 30 weeks during intensification.
  • Significant adverse predictors for OS were age >35 years, high white blood cell count, MLL rearrangement, allogeneic stem cell transplantation in first complete remission and <80% of the planned asparaginase dose delivered during intensification.
  • We conclude that the administration of this paediatric regimen is feasible and has considerable activity in adult ALL, particularly in younger patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Asparaginase / administration & dosage. Asparaginase / therapeutic use. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Fusion Proteins, bcr-abl. Humans. Male. Middle Aged. Remission Induction / methods. Stem Cell Transplantation. Survival Rate. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438471.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


42. Ohno R, Japan Adult Leukemia Study Group: Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. Curr Hematol Malig Rep; 2006 Sep;1(3):180-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy.
  • The presence of the Philadelphia chromosome (Ph) is associated with a very poor prognosis in acute lymphoblastic leukemia (ALL).
  • Although hematologic complete remission (CR) is achieved in 50% to 80% of adult patients by intensive chemotherapy in multicenter studies, long-term outcome is dismal, with overall survival of approximately 10%.
  • Currently, allogeneic hematopoietic stem cell transplantation (allo-SCT) is thought to be the only curative therapeutic modality for this leukemia in adults, but the long-term survival rates are about 40% or less, far from satisfactory.
  • Imatinib mesylate, a recently introduced specific tyrosine kinase inhibitor of BCR-ABL, in combination with chemotherapy, resulted in more than 90% hematologic CR in adult Ph-positive ALL, including molecular CR in more than 50% of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fusion Proteins, bcr-abl / antagonists & inhibitors. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Adult. Benzamides. Clinical Trials as Topic / statistics & numerical data. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Humans. Imatinib Mesylate. Kaplan-Meier Estimate. Methotrexate / administration & dosage. Multicenter Studies as Topic / statistics & numerical data. Piperazines / administration & dosage. Prednisolone / administration & dosage. Protein Kinase Inhibitors / administration & dosage. Pyrimidines / administration & dosage. Remission Induction. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Int J Hematol. 2004 Jan;79(1):79-84 [14979483.001]
  • [Cites] Nature. 1987 Feb 12-18;325(6105):635-7 [3027581.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4500-5 [15930265.001]
  • [Cites] Blood. 1992 Jun 1;79(11):3067-70 [1586748.001]
  • [Cites] Science. 1988 Feb 12;239(4841 Pt 1):775-7 [3422516.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):623-32 [12692601.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] Int J Hematol. 1998 Dec;68(4):421-9 [9885441.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3507-12 [15315963.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2636-42 [14669283.001]
  • [Cites] Cell. 1987 Oct 9;51(1):33-40 [2820585.001]
  • [Cites] Int J Hematol. 1998 Oct;68(3):279-89 [9846012.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1811-22 [11753600.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3691-8 [9345054.001]
  • [Cites] Blood Cells Mol Dis. 1997 Dec;23(3):380-94 [9446752.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1999-2007 [11264164.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3948-54 [16105974.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Blood. 2003 Jan 15;101(2):473-5 [12393385.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 1998 Jun 1;91(11):3995-4019 [9596644.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1536-43 [11861265.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):489-500 [16098062.001]
  • (PMID = 20425349.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8A1O1M485B / Imatinib Mesylate; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 2.7.10.2 / Fusion Proteins, bcr-abl; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; CVAD protocol
  • [Number-of-references] 37
  •  go-up   go-down


43. Montoya A, Tohen M, Vieta E, Casillas M, Chacón F, Polavieja P, Gilaberte I: Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: a 1-year, prospective, observational cohort study. J Affect Disord; 2010 Dec;127(1-3):50-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: a 1-year, prospective, observational cohort study.
  • BACKGROUND: Recent studies demonstrate that many Bipolar Disorder (BD) patients experience mild symptoms and/or suffer significant functional impairment during periods of syndromal remission, suggesting greater relapse risk and need for more intensive therapeutic strategies.
  • This study aimed to prospectively evaluate whether the presence of subsyndromal symptoms and level of functionality have long-term consequences in BD patients in syndromal remission.
  • METHODS: A 1-year, prospective, observational cohort study of BD patients in syndromal remission assessed participants at study entry and 3, 6 and 12months after baseline on a range of clinical, social and functional outcomes.
  • Finally, 398 patients with bipolar I disorder in syndromal remission were included.
  • After the 12-month, follow-up period, 87.6% of patients remained in syndromal remission, 79.9% of patients were free of subsyndromal symptoms, but only 53.5% had normal levels of functionality.
  • CONCLUSIONS: In a prospectively assessed BD cohort with all patients in syndromal remission at baseline, syndromal remission was not always accompanied by normal functioning and/or the presence subsyndromal symptoms.
  • Interventions, including medication and psychosocial approaches, should go beyond syndromal remission and target subsyndromal symptoms and functional recovery.
  • [MeSH-minor] Adaptation, Psychological. Adult. Antimanic Agents / therapeutic use. Cohort Studies. Diagnostic and Statistical Manual of Mental Disorders. Female. Follow-Up Studies. Humans. Interview, Psychological. Male. Middle Aged. Prospective Studies. Psychotropic Drugs / therapeutic use. Recurrence. Social Adjustment. Syndrome

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20557947.001).
  • [ISSN] 1573-2517
  • [Journal-full-title] Journal of affective disorders
  • [ISO-abbreviation] J Affect Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimanic Agents; 0 / Psychotropic Drugs
  •  go-up   go-down


44. Brenninkmeijer EE, Spuls PI, Lindeboom R, van der Wal AC, Bos JD, Wolkerstorfer A: Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. Br J Dermatol; 2010 Oct;163(4):823-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological changes were evaluated and duration of remission was monitored during a 6-month follow-up period.
  • [MeSH-minor] Adult. Aged. Biopsy. Dermatologic Agents / adverse effects. Dermatologic Agents / therapeutic use. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Skin / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Eczema.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. Clobetasol .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.
  • (PMID = 20491772.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Glucocorticoids; ADN79D536H / Clobetasol
  •  go-up   go-down


45. Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejón A, Vergara M, Campo R, Brullet E: Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm Bowel Dis; 2006 Aug;12(8):692-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease.
  • BACKGROUND: Thiopurinic immunomodulators are effective for maintaining symptom remission in Crohn's disease.
  • The present study aimed to determine whether remission induced by thiopurinic immunomodulators returns levels of quality of life and psychological well-being to normal.
  • Cases were 33 patients with Crohn's disease treated with azathioprine or 6-mercaptopurine and in stable remission for at least 6 months.
  • CONCLUSIONS: Thiopurinic immunomodulator-induced remission restores normal levels of quality of life and psychological well-being in Crohn's disease patients.
  • [MeSH-minor] Adult. Anxiety / diagnosis. Anxiety / etiology. Case-Control Studies. Depression / diagnosis. Depression / etiology. Female. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917223.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


46. Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R, Diverio D, Frustaci A, Loglisci G, Mancini M, Santopietro M, Stefanizzi C, Volpicelli P, Vozella F, Alimena G: "Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res; 2010 Nov;34(11):1472-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Age Factors. Aged. Benzamides. Comorbidity. Dose-Response Relationship, Drug. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20708799.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


47. Monastero R, Camarda C, Pipia C, Camarda R: Prognosis of migraine headaches in adolescents: a 10-year follow-up study. Neurology; 2006 Oct 24;67(8):1353-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 55 subjects with migraine headaches at baseline, 41.8% had persistent migraine, 38.2% had experienced remission, and 20.0% transformed to tension-type headache.
  • [MeSH-minor] Adolescent. Age Distribution. Child. Chronic Disease. Female. Follow-Up Studies. Humans. Logistic Models. Male. Medical Records. Migraine with Aura / physiopathology. Migraine without Aura / physiopathology. Odds Ratio. Outcome Assessment (Health Care). Prognosis. Prospective Studies. Remission, Spontaneous. Risk. Sex Distribution. Tension-Type Headache / etiology. Time Factors

  • Genetic Alliance. consumer health - Migraine.
  • MedlinePlus Health Information. consumer health - Migraine.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060559.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Mok CC, Ying KY, Yim CW, Ng WL, Wong WS: Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus; 2009 Oct;18(12):1091-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were followed for the following outcomes: remission rate at 12 months, renal flares, extra-renal flares and renal function deterioration.
  • [MeSH-minor] Adult. Creatinine / blood. Female. Humans. Middle Aged. Prednisolone / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Membranous nephropathy.
  • MedlinePlus Health Information. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762384.001).
  • [ISSN] 1477-0962
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 9PHQ9Y1OLM / Prednisolone; AYI8EX34EU / Creatinine; MRK240IY2L / Azathioprine
  •  go-up   go-down


49. Cvetić T, Vuković O, Britvić D, Ivković M, Dukić-Dejanović S, Lecić-Tosevski D: Comparative analysis of soft neurological signs in positive and negative subtype of schizophrenia. Psychiatr Danub; 2009 Jun;21(2):174-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS AND METHODS: 66 patients with schizophrenia were evaluated with the Positive and Negative Syndrome Scale to classify the subtype of schizophrenia: positive subtype (36 patients) and negative subtype (30 patients), all of which were entering into remission.
  • [MeSH-minor] Adult. Female. Humans. Male. Psychometrics. Young Adult


50. Willemze R, Labar B: Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation? Semin Hematol; 2007 Oct;44(4):267-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation?
  • Allogeneic stem cell transplantation (alloSCT) or autologous SCT (autoSCT) and intensive consolidation/intensification courses plus maintenance chemotherapy for 1 to 2 years are currently the major options for post-remission treatment of adult patients with acute lymphoblastic leukemia (ALL) in first remission.
  • Herein, we try to dissect data from these randomized trials to evaluate the role of autoSCT in patients with ALL in complete remission.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation / methods. Transplantation, Autologous
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / mortality. Disease-Free Survival. Evidence-Based Medicine. Humans. Randomized Controlled Trials as Topic / methods. Remission Induction. Survival Rate. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961726.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


51. Villa G, Balleari E, Carletto M, Grosso M, Clavio M, Piccardo A, Rebella L, Tommasi L, Morbelli S, Peschiera F, Gobbi M, Ghio R: Staging and therapy monitoring of multiple myeloma by 99mTc-sestamibi scintigraphy: a five year single center experience. J Exp Clin Cancer Res; 2005 Sep;24(3):355-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 51/68 MM patients had active disease (AD), 11/62 were in complete remission (CR) and 6/68 in partial remission (PR) after chemotherapy.
  • In conclusion, these results indicate that 99mTc-MIBI scintigraphy closely reflects myeloma disease activity in the bone marrow, and that a negative 99mTc-MIBI scan in patients with suspected MM clearly, though not absolutely, indicates absence of disease or clinical remission.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270521.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


52. Dawson DA, Stinson FS, Chou SP, Grant BF: Three-year changes in adult risk drinking behavior in relation to the course of alcohol-use disorders. J Stud Alcohol Drugs; 2008 Nov;69(6):866-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-year changes in adult risk drinking behavior in relation to the course of alcohol-use disorders.
  • RESULTS: There were positive changes in all consumption measures associated with developing an AUD and negative changes associated with remission of an AUD, even among individuals who continued to drink.
  • Increases and decreases associated with onset and offset of dependence exceeded those associated with onset/ offset of abuse only, and the decreases associated with full remission from dependence exceeded those associated with partial remission.

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Alcohol Depend. 2004 Jun 11;74(3):223-34 [15194200.001]
  • [Cites] J Stud Alcohol. 2004 Mar;65(2):255-65 [15151358.001]
  • [Cites] Addiction. 2004 Sep;99(9):1111-20 [15317631.001]
  • [Cites] J Psychiatr Res. 2005 Jan;39(1):1-9 [15504418.001]
  • [Cites] J Stud Alcohol. 1990 Sep;51(5):448-56 [2232799.001]
  • [Cites] Int J Addict. 1990 Jun;25(6):599-619 [2265865.001]
  • [Cites] J Stud Alcohol. 1992 Mar;53(2):142-53 [1313935.001]
  • [Cites] J Stud Alcohol. 1993 Mar;54(2):178-88 [8459712.001]
  • [Cites] Addiction. 1993 Aug;88(8):1079-90 [8401162.001]
  • [Cites] Drug Alcohol Depend. 2004 Jun 11;74(3):235-44 [15194201.001]
  • [Cites] Addiction. 1993 Nov;88(11):1509-18 [8286996.001]
  • [Cites] J Stud Alcohol. 1996 May;57(3):289-304 [8709588.001]
  • [Cites] Am J Public Health. 1996 Jul;86(7):966-72 [8669520.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Jun;20(4):771-9 [8800398.001]
  • [Cites] J Stud Alcohol. 1996 Sep;57(5):494-506 [8858547.001]
  • [Cites] Alcohol Alcohol. 1997 Jul-Aug;32(4):527-35 [9269861.001]
  • [Cites] Drug Alcohol Depend. 1997 Sep 25;47(3):195-205 [9306045.001]
  • [Cites] Drug Alcohol Depend. 1997 Sep 25;47(3):207-16 [9306046.001]
  • [Cites] Ann Epidemiol. 1997 Nov;7(8):542-9 [9408550.001]
  • [Cites] J Abnorm Psychol. 2004 Nov;113(4):483-98 [15535782.001]
  • [Cites] Am J Epidemiol. 2005 Mar 1;161(5):423-33 [15718478.001]
  • [Cites] Drug Alcohol Depend. 2005 Jun 1;78(3):339-44 [15893165.001]
  • [Cites] J Stud Alcohol. 2005 May;66(3):313-22 [16047520.001]
  • [Cites] Drug Alcohol Depend. 2005 Dec 12;80(3):337-47 [15946805.001]
  • [Cites] Alcohol Clin Exp Res. 2005 Nov;29(11):2015-21 [16340459.001]
  • [Cites] J Abnorm Psychol. 2005 Nov;114(4):612-26 [16351384.001]
  • [Cites] Addiction. 2006 Jan;101(1):91-9 [16393195.001]
  • [Cites] J Stud Alcohol. 2006 Jul;67(4):552-61 [16736075.001]
  • [Cites] Psychol Med. 2006 Jul;36(7):931-41 [16563205.001]
  • [Cites] J Stud Alcohol. 2006 Nov;67(6):917-25 [17061010.001]
  • [Cites] Alcohol Clin Exp Res. 2007 Feb;31(2):293-8 [17250622.001]
  • [Cites] Addict Behav. 2007 Apr;32(4):819-35 [16860940.001]
  • [Cites] Drug Alcohol Depend. 2007 Jun 15;89(1):82-92 [17240085.001]
  • [Cites] Alcohol Clin Exp Res. 2007 Jun;31(6):1020-30 [17403064.001]
  • [Cites] Alcohol Clin Exp Res. 2007 Jun;31(6):928-38 [17403069.001]
  • [Cites] Drug Alcohol Depend. 2008 May 1;95(1-2):62-72 [18243584.001]
  • [Cites] J Stud Alcohol. 1999 Nov;60(6):790-9 [10606491.001]
  • [Cites] Addiction. 1999 Jun;94(6):843-55 [10665074.001]
  • [Cites] J Stud Alcohol. 2000 Mar;61(2):290-300 [10757140.001]
  • [Cites] Alcohol Clin Exp Res. 2000 Jun;24(6):892-901 [10888080.001]
  • [Cites] Alcohol Clin Exp Res. 2000 Jun;24(6):914-23 [10888082.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2001 Jan;40(1):83-90 [11195569.001]
  • [Cites] J Abnorm Psychol. 2001 Aug;110(3):378-91 [11502081.001]
  • [Cites] J Stud Alcohol. 2001 Jul;62(4):457-66 [11523533.001]
  • [Cites] J Stud Alcohol. 2001 Sep;62(5):589-604 [11702798.001]
  • [Cites] Am J Epidemiol. 2002 Feb 1;155(3):242-8 [11821249.001]
  • [Cites] J Consult Clin Psychol. 2002 Feb;70(1):67-78 [11860058.001]
  • [Cites] Addiction. 2002 Mar;97(3):301-10 [11964106.001]
  • [Cites] J Gen Intern Med. 2002 May;17(5):382-6 [12047737.001]
  • [Cites] J Stud Alcohol. 2002 Jul;63(4):397-403 [12160097.001]
  • [Cites] J Stud Alcohol. 2002 Sep;63(5):568-76 [12380853.001]
  • [Cites] Addiction. 2002 Nov;97(11):1427-37 [12410783.001]
  • [Cites] Health Psychol. 2003 Jan;22(1):79-87 [12558205.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2003 Feb;13(1):2-11 [12772432.001]
  • [Cites] Drug Alcohol Depend. 2003 Jul 20;71(1):7-16 [12821201.001]
  • [Cites] J Stud Alcohol. 2004 Mar;65(2):204-12 [15151351.001]
  • [Cites] Arch Gen Psychiatry. 2004 Aug;61(8):807-16 [15289279.001]
  • (PMID = 18925345.001).
  • [ISSN] 1937-1888
  • [Journal-full-title] Journal of studies on alcohol and drugs
  • [ISO-abbreviation] J Stud Alcohol Drugs
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  • [Other-IDs] NLM/ PMC2583373
  •  go-up   go-down


53. Marzano AV, Trevisan V, Lazzari R, Crosti C: Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. J Dermatolog Treat; 2010 May;21(3):140-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all five patients complete remission was achieved within a mean time of 6 weeks and no relapses occurred; in three cases, tacrolimus was discontinued, while the remaining two patients were applying the drug as maintenance therapy at the time of writing.
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Early Diagnosis. Female. Follow-Up Studies. Humans. Middle Aged. Retrospective Studies. Sampling Studies. Severity of Illness Index. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Pyoderma gangrenosum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903010.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


54. Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC, Oldani E, Grassi A, Intermesoli T, Micò C, Rossi G, Fabris P, Lambertenghi-Deliliers G, Angelucci E, Barbui T, Bassan R, Rambaldi A: Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica; 2007 May;92(5):612-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
  • BACKGROUND AND OBJECTIVES: The molecular analysis of minimal residual disease (MRD) may provide information on the risk of recurrence in patients with acute lymphoblastic leukemia (ALL).
  • Forty-three adult patients with ALL were studied to correlate the kinetics of MRD clearance before and after allogeneic hematopoietic stem cell transplantation.
  • RESULTS: At 36 months, the overall survival of patients who underwent transplantation in hematologic remission (n= 37) was 80% for those who were PCR-negative before transplantation (n= 12) compared to 49% for PCR-positive patients (n= 25)(p=0.17).
  • INTERPRETATION AND CONCLUSIONS: The kinetics of MRD clearance may help to identify patients at high risk of leukemia relapse after allogeneic stem cell transplantation.
  • Patients not achieving an early molecular remission after transplantation require prompt and appropriate pre-emptive treatments such as infusions of donor lymphocytes or new experimental drugs.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Transplantation, Homologous
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Basic Helix-Loop-Helix Transcription Factors / genetics. Benzamides. Biomarkers, Tumor / blood. Clinical Trials as Topic / statistics & numerical data. Cohort Studies. Combined Modality Therapy. Female. Fusion Proteins, bcr-abl / blood. Gene Deletion. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Humans. Imatinib Mesylate. Kaplan-Meier Estimate. Kinetics. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / surgery. Male. Middle Aged. Multicenter Studies as Topic. Myeloid-Lymphoid Leukemia Protein / blood. Neoplasm, Residual. Oncogene Proteins, Fusion / blood. Piperazines / administration & dosage. Polymerase Chain Reaction. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / surgery. Proto-Oncogene Proteins / genetics. Pyrimidines / administration & dosage. Remission Induction. Risk. Survival Analysis. Survival Rate. Translocation, Genetic. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488684.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Proto-Oncogene Proteins; 0 / Pyrimidines; 135471-20-4 / TAL1 protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


55. Ba MC, Cui SZ, Lin SQ, Tang YQ, Wu YB, Wang B, Zhang XL: Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol; 2010 Apr 21;16(15):1901-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically complete remission of ascites and related symptoms were achieved in 14 patients, and partial remission was achieved in 2 patients.
  • Two patients with partial remission suffered from port site seeding and tumor metastasis,and died 2 and 3 mo after treatment.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / pharmacology. Female. Fluorouracil / pharmacology. Humans. Male. Middle Aged. Organoplatinum Compounds / pharmacology. Perfusion. Remission Induction

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2003 Jul;83(3):147-53 [12827682.001]
  • [Cites] In Vivo. 2009 Jan-Feb;23(1):187-90 [19368148.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):358-61 [16112182.001]
  • [Cites] Suppl Tumori. 2005 May-Jun;4(3):S122-3 [16437944.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1144-53 [16456817.001]
  • [Cites] J Gastrointest Surg. 2006 Jul-Aug;10(7):1038-43 [16843875.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):682-5 [16631341.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):625-7 [16822641.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5 [17481516.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Jul;16(3):653-66, x [17606199.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3274-82 [17653591.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):339-44 [17943387.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):154-8 [17640844.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):542-6 [17929098.001]
  • [Cites] World J Gastroenterol. 2008 Feb 28;14(8):1159-66 [18300340.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2008 Aug;18(4):426-8 [18716551.001]
  • [Cites] Eur J Surg Oncol. 2005 Jun;31(5):540-3 [15922890.001]
  • (PMID = 20397270.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2856833
  • [Keywords] NOTNLM ; Chemotherapy / Gastric cancer / Intraperitoneal hyperthermic perfusion / Laparoscopy / Malignant ascites
  •  go-up   go-down


56. Aminzadeh A, Demircay Z, Ocak K, Soyletir G: Prevention of chronic furunculosis with low-dose azithromycin. J Dermatolog Treat; 2007;18(2):105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: At the end of 3 months of therapy, azithromycin was found to be effective in 19 (79.2%) of 24 patients; 18 of these patients remained in remission during the 3 months of follow-up.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Chronic Disease. Drug Administration Schedule. Female. Humans. Male. Methicillin Resistance. Microbial Sensitivity Tests. Middle Aged. Prospective Studies. Severity of Illness Index. Staphylococcus aureus / drug effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. AZITHROMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520467.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 83905-01-5 / Azithromycin
  •  go-up   go-down


57. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE: Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer; 2007 Apr 1;109(7):1355-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
  • BACKGROUND: From 20% to 30% of patients with acute promyelocytic leukemia (APL) who are treated with all-trans retinoic acid (ATRA) develop recurrent disease.
  • Patients received ATO 0.15 mg/kg intravenously until they achieved a bone marrow complete remission (CR).
  • All 7 evaluable patients achieved molecular remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Arsenicals / administration & dosage. Humans. Middle Aged. Oxides / administration & dosage. Remission Induction. Treatment Outcome. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17326049.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


58. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG: The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma; 2007 Oct;48(10):1931-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
  • The natural history and outcome of salvage treatment for patients with fludarabine-refractory chronic lymphocytic leukemia who are either refractory to alemtuzumab ("double-refractory") or ineligible for alemtuzumab due to bulky lymphadenopathy ("bulky fludarabine-refractory") have not been described.
  • All four patients who underwent SCT as first salvage achieved complete remission.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antibodies, Neoplasm / pharmacology. Drug Resistance, Neoplasm. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphatic Diseases / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / pharmacology. Female. Humans. Male. Middle Aged. Models, Biological. Rituximab. Stem Cell Transplantation / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Oct;48(10):1885-7 [17917953.001]
  • (PMID = 17917961.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


59. Lertkhachonsuk AA, Israngura N, Wilailak S, Tangtrakul S: Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. Int J Gynecol Cancer; 2009 Jul;19(5):985-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study is to compare the remission and complication rates of actinomycin D (Act-D) and methotrexate-folinic acid (MTX-FA) as single-agent treatments of stage I, low-risk gestational trophoblastic neoplasia (GTN).
  • All 20 women (100%) in the Act-D arm achieved remission compared with 14 (73.6%) in 19 women in the MTX-FA arm (P = 0.02).
  • [MeSH-minor] Adult. Dactinomycin / administration & dosage. Female. Humans. Maximum Tolerated Dose. Methotrexate / administration & dosage. Neoplasm Staging. Pregnancy. Prognosis. Survival Rate. Treatment Outcome. Vitamin B Complex / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574798.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 12001-76-2 / Vitamin B Complex; 1CC1JFE158 / Dactinomycin; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


60. Pollack MH, Endicott J, Liebowitz M, Russell J, Detke M, Spann M, Ball S, Swindle R: Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res; 2008 Oct;42(12):1042-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using comparison norms, the current work describes the clinical relevance of these functional improvements in terms of return to normative functioning and symptom remission.
  • METHODS: Data were pooled at the individual patient level from three double-blind, placebo-controlled trials of duloxetine treatment (9-10 weeks acute therapy, dose ranges 60-120mg).
  • RESULTS: Adult patients (mean age=42.4 years; 65% women) were randomly assigned to duloxetine (N=668) or placebo (N=495).
  • Remission defined as a HAMA total score at endpoint of 10, compared with 7, captured a greater proportion of patients who were functionally in remission.
  • Attention to role functioning and quality of life may refine our definition of remission when using standard symptom measures of anxiety.

  • Genetic Alliance. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • Hazardous Substances Data Bank. DULOXETINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18221755.001).
  • [ISSN] 0022-3956
  • [Journal-full-title] Journal of psychiatric research
  • [ISO-abbreviation] J Psychiatr Res
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurotransmitter Uptake Inhibitors; 0 / Placebos; 0 / Thiophenes; 9044SC542W / Duloxetine Hydrochloride
  •  go-up   go-down


61. Kobayashi T, Naganuma M, Okamoto S, Hisamatsu T, Inoue N, Ichikawa H, Takayama T, Saito R, Sujino T, Ogata H, Iwao Y, Hibi T: Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol; 2010 Nov;45(11):1129-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we propose that treatment of severe UC with CSA requires consideration of both initial remission and long-term maintenance as management goals.
  • [MeSH-minor] Adolescent. Adult. Aged. Colonoscopy / methods. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Intestinal Mucosa / pathology. Life Tables. Male. Middle Aged. Prognosis. Retrospective Studies. Severity of Illness Index. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gastroenterol Hepatol. 2005 Jan;17(1):79-84 [15647646.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] J Gastroenterol. 2003;38(8):740-6 [14505127.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):417-29 [12167685.001]
  • [Cites] J Gastroenterol. 2010 Sep;45(9):936-43 [20401498.001]
  • [Cites] Inflamm Bowel Dis. 2009 Sep;15(9):1295-301 [19340881.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Mar;27 Suppl 1:15-21 [18307645.001]
  • [Cites] Am J Gastroenterol. 2009 Nov;104(11):2760-7 [19623172.001]
  • [Cites] Gut. 2006 Apr;55(4):437-41 [16531519.001]
  • [Cites] World J Gastroenterol. 2008 Sep 28;14(36):5508-11 [18810767.001]
  • [Cites] Nature. 1992 Jun 25;357(6380):692-4 [1377361.001]
  • [Cites] Gastroenterol Clin Biol. 2005 Mar;29(3):231-5 [15864171.001]
  • [Cites] J Gastroenterol. 2006 Jan;41(1):10-6 [16501852.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Oct;12(10):973-8 [9798801.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):637-42 [18047542.001]
  • [Cites] Am J Gastroenterol. 2008 Apr;103(4):937-43 [18177449.001]
  • [Cites] Gut. 1996 Jun;38(6):905-10 [8984031.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):760-5 [16716758.001]
  • [Cites] N Engl J Med. 1994 Jun 30;330(26):1841-5 [8196726.001]
  • [Cites] Inflamm Bowel Dis. 2009 Jan;15(1):141-2 [18266232.001]
  • [Cites] BMC Gastroenterol. 2007 Mar 27;7:13 [17389040.001]
  • [Cites] Dig Liver Dis. 2004 Jul;36(7):461-6 [15285525.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1587-92 [10364029.001]
  • [Cites] Inflamm Bowel Dis. 1999 Feb;5(1):1-10 [10028443.001]
  • [Cites] Gut. 2006 Jan;55(1):47-53 [15972298.001]
  • (PMID = 20614157.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


62. Holle JU, Gross WL, Holl-Ulrich K, Ambrosch P, Noelle B, Both M, Csernok E, Moosig F, Schinke S, Reinhold-Keller E: Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis; 2010 Nov;69(11):1934-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All achieved a response to treatment, 34% achieved complete remission, 1-4 relapses occurred in 46%, 5 (10%) had generalised disease (median 6 years after onset).
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Antineutrophil Cytoplasmic / blood. Biomarkers / blood. Disease Progression. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Phenotype. Prognosis. Recurrence. Young Adult

  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20511614.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic; 0 / Biomarkers; 0 / Immunosuppressive Agents
  •  go-up   go-down


63. Bertram MY, Vos T: Quantifying the duration of pre-diabetes. Aust N Z J Public Health; 2010 Jun;34(3):311-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The result of this meta-analysis as well as information on prevalence, remission of pre-diabetes and transition to diabetes from an Australian cohort study, were used in the software program DisMod to calculate duration.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Australia / epidemiology. Evidence-Based Medicine. Female. Humans. Male. Middle Aged. Risk. Sex Factors. Time Factors


64. Di Bona E, Pogliani E, Rossi G, Lerede T, D'Emilio A, Vespignani M, Rodeghiero F, Barbui T, Bassan R: Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients. Leuk Lymphoma; 2005 Jun;46(6):879-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients.
  • Idarubicin-based induction programs in acute lymphoblastic leukemia (ALL) account for 75?
  • -?85% of complete remission rate.
  • A small amount of patients exhibit primary refractoriness, and approximately 60% of those achieving a remission eventually relapse.
  • With 'A', 21 achieved a complete remission (CR), 10 were refractory and 5 died early.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Methotrexate / administration & dosage. Mitoxantrone / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Female. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019533.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; BZ114NVM5P / Mitoxantrone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


65. Nisticò SP, Saraceno R, Schipani C, Costanzo A, Chimenti S: Different applications of monochromatic excimer light in skin diseases. Photomed Laser Surg; 2009 Aug;27(4):647-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We observed complete remission in more than 50% of patients with plaque psoriasis and palmoplantar dermatoses, respectively, complete remission in all patients affected by mycosis fungoides, excellent repigmentation in one third of vitiligo patients, hair regrowth in three patients with alopecia areata, an overall improvement in prurigo nodularis, a partial remission in patients affected by localized scleroderma, and a complete remission in most of the patients with genital lichen sclerosus and granuloma annulare.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Ultraviolet Therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563242.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Nyenwe EA, Dagogo-Jack S: Iodine deficiency disorders in the iodine-replete environment. Am J Med Sci; 2009 Jan;337(1):37-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dietary iodine supplementation alone resulted in complete remission of IDD in the subjects, including the 2 patients with hypothyroidism.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 1998 Jul;139(1):14-5 [9703371.001]
  • [Cites] Afr J Med Med Sci. 1995 Sep;24(3):211-7 [8798954.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3401-8 [9768638.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):561-6 [10022416.001]
  • [Cites] Conn Med. 2005 Feb;69(2):73-7 [15779603.001]
  • [Cites] Ther Drug Monit. 2005 Apr;27(2):178-85 [15795649.001]
  • [Cites] Thyroid. 2005 Jul;15(7):692-9 [16053386.001]
  • [Cites] N Engl J Med. 2006 Jun 29;354(26):2819-21 [16807421.001]
  • [Cites] J Nutr. 2007 Mar;137(3):573-7 [17311942.001]
  • [Cites] N Engl J Med. 2007 Sep 20;357(12):1263-4 [17881763.001]
  • [Cites] Postgrad Med J. 2001 Apr;77(906):217-20 [11264481.001]
  • [Cites] Thyroid. 2002 Oct;12(10):867-78 [12487769.001]
  • [Cites] Lancet. 2003 Nov 29;362(9398):1859-60 [14654340.001]
  • [Cites] J Clin Invest. 1989 Mar;83(3):764-70 [2921318.001]
  • [Cites] Endocr Res. 1994 Aug;20(3):247-57 [7995255.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2574-6 [7673397.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3398-400 [9768637.001]
  • (PMID = 19155752.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK067269-03; United States / NCRR NIH HHS / RR / M01 RR00211; United States / NCRR NIH HHS / RR / M01 RR000211; United States / NIDDK NIH HHS / DK / R01 DK067269; United States / NIDDK NIH HHS / DK / R01 DK067269-03
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin; 9679TC07X4 / Iodine
  • [Other-IDs] NLM/ NIHMS85795; NLM/ PMC2634852
  •  go-up   go-down


67. Wijkstra J, Burger H, van den Broek WW, Birkenhäger TK, Janzing JG, Boks MP, Bruijn JA, van der Loos ML, Breteler LM, Verkes RJ, Nolen WA: Long-term response to successful acute pharmacological treatment of psychotic depression. J Affect Disord; 2010 Jun;123(1-3):238-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term response to successful acute pharmacological treatment of psychotic depression.
  • BACKGROUND: Data about follow-up after acute pharmacological treatment of psychotic depression are scarce.
  • METHODS: A 4 month open follow-up was done, preferentially with same medication as during acute treatment, of patients (n=59) with DSM-IV-TR major depressive disorder with psychotic features, aged 18 to 65 years, who had completed as responders an acute double-blind 7 week trial with imipramine, venlafaxine or venlafaxine plus quetiapine.
  • Almost all patients (86.4%; 51/59) remained responder while remission rate increased from 59.3% (35/59) to 86.8% (46/53), independent of treatment.
  • CONCLUSIONS: Continuation treatment with the same medication that was effective in the acute treatment trial, remained effective during the 4 month follow-up in many patients leading to further improvement, and was well tolerated.
  • [MeSH-minor] Adult. Double-Blind Method. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Long-Term Care. Male. Middle Aged. Netherlands. Quetiapine Fumarate. Treatment Outcome. Venlafaxine Hydrochloride

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • Hazardous Substances Data Bank. IMIPRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19880189.001).
  • [ISSN] 1573-2517
  • [Journal-full-title] Journal of affective disorders
  • [ISO-abbreviation] J Affect Disord
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antipsychotic Agents; 0 / Cyclohexanols; 0 / Dibenzothiazepines; 2S3PL1B6UJ / Quetiapine Fumarate; 7D7RX5A8MO / Venlafaxine Hydrochloride; OGG85SX4E4 / Imipramine
  •  go-up   go-down


68. Mattison RJ, Larson RA: Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Curr Opin Oncol; 2009 Nov;21(6):601-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia.
  • PURPOSE OF REVIEW: Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and outcomes vary by patient age, immunophenotype, and clinical, cytogenetic and molecular features.
  • SUMMARY: Available data indicate no clear consensus as to whether there is an advantage to allogeneic HCT over modern chemotherapy for adults with ALL with standard risk features while in the first complete remission (CR1).
  • However, allogeneic HCT is recommended in CR1 for patients with 'high-risk' ALL and for those in a second complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adult. Humans. Remission Induction. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19713843.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 53
  •  go-up   go-down


69. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ: Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology; 2007 Feb;45(2):307-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Adding ADV to LAM in HBeAg-negative CHB patients with LAM resistance effectively suppresses HBV replication inmost of them and induces biochemical remission that can be maintained in all of them at least for 3 years without any evidence of development of resistance to ADV.
  • [MeSH-minor] Adult. Aged. DNA, Viral / blood. Drug Therapy, Combination. Female. Hepatitis B virus / genetics. Humans. Male. Middle Aged. Mutation / genetics. Salvage Therapy / methods. Treatment Outcome. Virus Replication / drug effects

  • Genetic Alliance. consumer health - Hepatitis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2007 Feb;45(2):266-8 [17256763.001]
  • (PMID = 17256746.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Hepatitis B e Antigens; 0 / Organophosphonates; 2T8Q726O95 / Lamivudine; JAC85A2161 / Adenine; U6Q8Z01514 / adefovir dipivoxil
  •  go-up   go-down


70. Anzaar F, Gallagher MJ, Bhat P, Arif M, Farooqui S, Foster CS: Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis. Cornea; 2008 Sep;27(8):884-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All 6 patients experienced complete remission of their AKC and an increase in visual acuity.
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Cyclosporine / therapeutic use. Drug Therapy, Combination. Female. Humans. Immunoglobulin G / therapeutic use. Infusions, Intravenous. Male. Middle Aged. Retrospective Studies. Tacrolimus / therapeutic use. Visual Acuity

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724148.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; CUJ2MVI71Y / daclizumab; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


71. Stringer DE, Gilbert DH, Herford AS, Boyne PJ: A method of treating the patient with postpubescent juvenile rheumatoid arthritis. J Oral Maxillofac Surg; 2007 Oct;65(10):1998-2004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment protocols for the prepubescent patient (<12 years for girls and 14 years for boys), as well as for the adult, have been established.
  • Patients were in disease remission at the time of surgery, and all presented with the same skeletal/dental deformity and condylar destruction.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Cephalometry. Child. Child, Preschool. Facies. Female. Follow-Up Studies. Humans. Longitudinal Studies. Malocclusion, Angle Class II / etiology. Malocclusion, Angle Class II / surgery. Mandible / abnormalities. Mandible / surgery. Maxilla / abnormalities. Maxilla / surgery. Open Bite / etiology. Open Bite / surgery. Orthodontics, Corrective / methods. Osteotomy, Le Fort / methods. Pilot Projects. Treatment Outcome. Vertical Dimension


72. Fujita A, Azuma H, Kitamura T, Takahashi K, Akechi T, Furukawa TA: Adequacy of continuation and maintenance treatments for major depression in Japan. J Psychopharmacol; 2008 Mar;22(2):153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Guidelines for treating depression often recommend continuing antidepressants at least for 6 months after remission.
  • [MeSH-minor] Adult. Cohort Studies. Continuity of Patient Care. Dose-Response Relationship, Drug. Female. Humans. Japan. Long-Term Care. Longitudinal Studies. Male. Middle Aged. Prospective Studies. Quality Assurance, Health Care / statistics & numerical data. Secondary Prevention. Treatment Outcome

  • Genetic Alliance. consumer health - Depression.
  • Genetic Alliance. consumer health - Major depressive disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • Hazardous Substances Data Bank. IMIPRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18208923.001).
  • [ISSN] 0269-8811
  • [Journal-full-title] Journal of psychopharmacology (Oxford, England)
  • [ISO-abbreviation] J. Psychopharmacol. (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic; OGG85SX4E4 / Imipramine
  •  go-up   go-down


73. Bondolfi G, Aubry JM, Golaz J, Gex-Fabry M, Gervasoni N, Bertschy G: A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. Swiss Med Wkly; 2006 Feb 4;136(5-6):78-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study.
  • QUESTIONS UNDER STUDY/PRINCIPLES: We describe the proportion of severely depressed outpatients reaching complete remission at the different stages of a drug treatment algorithm.
  • From this group, 86 patients dropped out (65.6%), 40 reached complete remission (30.5%) and 5 patients did not reach remission at all (3.8%).
  • [MeSH-minor] Adult. Clinical Protocols. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Remission Induction. Serotonin Uptake Inhibitors / therapeutic use. Switzerland

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Depression.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633950.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Serotonin Uptake Inhibitors
  •  go-up   go-down


74. Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander AR, Bacher U: Second allogeneic stem cell transplantation in myeloid malignancies. Acta Haematol; 2009;122(4):185-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We retrospectively analyzed outcomes of the second allo-SCT in 25 patients who received at least 2 allografts from related/unrelated donors due to relapse of acute myeloid leukemia, myelodysplastic syndrome or myelofibrosis after the first SCT.
  • A minority of the acute myeloid leukemia/myelodysplastic syndrome patients had reached complete hematological remission before the second SCT (6/25, 24%).
  • Complete remission was achieved in all 21 cases with available data after the second SCT, but relapse was seen in 11/25 patients (44%).
  • After a median follow-up of 18 months (range 6-47), 8/25 patients (32%) were still alive, and of those, 6 (24%) were in stable remission.
  • In conclusion, a second SCT offers the chance of stable remission for some patients relapsing with a myeloid malignancy after a first allo-SCT, although high treatment-related mortality and relapse rates remain a problem.
  • [MeSH-major] Leukemia, Myeloid, Acute / surgery. Myelodysplastic Syndromes / surgery. Peripheral Blood Stem Cell Transplantation. Primary Myelofibrosis / surgery
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Child, Preschool. Female. Graft Survival. Graft vs Host Disease / etiology. Humans. Leukemia, Myelomonocytic, Juvenile / surgery. Male. Middle Aged. Polycythemia / complications. Recurrence. Reoperation. Retrospective Studies. Salvage Therapy. Transplantation Conditioning. Transplantation, Homologous. Young Adult


75. Bradford J, Fischer G: Long-term management of vulval lichen sclerosus in adult women. Aust N Z J Obstet Gynaecol; 2010 Apr;50(2):148-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term management of vulval lichen sclerosus in adult women.
  • BACKGROUND: Adult vulval lichen sclerosus (VLS) is usually a lifelong disease with an estimated remission rate after treatment of only 16% [Arch Dermatol 2004; 140 (6): 709].
  • Although superpotent topical corticosteroid (TCS) is the validated gold standard treatment to induce remission, little data are available on how remission should be maintained.
  • AIMS: We present a retrospective chart review of 129 adult patients with VLS who have been under surveillance by the authors for a minimum duration of three years.
  • METHODS: Remission was maintained in most patients with low-to-moderate potency TCS.
  • All subjects' symptoms, signs, treatment regimes and response to treatment including compliance, symptom remission, disease progression with scarring, squamous cell carcinoma and side effects were recorded.
  • Symptom remission was achieved in 98% of compliant and 75% of non-compliant patients (P = 0.001) Progression of disease with scarring was not encountered in any of the compliant patients, but was seen in 35% of non-compliant patients (P = 0.0001).
  • CONCLUSIONS: Long-term treatment of adult VLS with individualised regimes using moderate potency TCS is safe and effective.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antifungal Agents / therapeutic use. Candidiasis / drug therapy. Carcinoma, Squamous Cell / diagnosis. Cicatrix / chemically induced. Dermatitis / etiology. Disease Progression. Female. Humans. Middle Aged. Patient Compliance. Remission Induction. Retrospective Studies. Treatment Outcome. Vulvar Neoplasms / diagnosis. Young Adult

  • MedlinePlus Health Information. consumer health - Steroids.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20522071.001).
  • [ISSN] 1479-828X
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antifungal Agents
  •  go-up   go-down


76. Hettinga YM, Verdonck LF, Fijnheer R, Rijkers GT, Rothova A: Anterior uveitis: a manifestation of graft-versus-host disease. Ophthalmology; 2007 Apr;114(4):794-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment, both systemic and topical, directed to chronic GVHD induced remission of uveitis in all patients along with amelioration of other signs of GVHD.
  • CONCLUSIONS: Anterior uveitis occurred in the wake of the acute exacerbation of chronic GVHD after HSCT and may represent an ocular manifestation of chronic GVHD.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aqueous Humor / metabolism. Chronic Disease. Cytokines / metabolism. Enzyme-Linked Immunosorbent Assay. Gastrointestinal Diseases / complications. Glucocorticoids / therapeutic use. Hematopoietic Stem Cell Transplantation. Humans. Leukemia, Myeloid / therapy. Lymphoma, Mantle-Cell / therapy. Male. Middle Aged. Multiple Myeloma / therapy. Retrospective Studies. Skin Diseases / complications. Transplantation, Homologous

  • Genetic Alliance. consumer health - Uveitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187864.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Glucocorticoids
  •  go-up   go-down


77. Docherty JP, Bossie CA, Lachaux B, Bouhours P, Zhu Y, Lasser R, Gharabawi GM: Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol; 2007 Jan;22(1):51-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-based and clinician-based support for the remission criteria in schizophrenia.
  • This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria.
  • Remission criteria included severity (absent-mild ratings on core symptoms of the Positive and Negative Syndrome Scale) and duration (> or =6 months) components.
  • Among patients who met remission criteria during the study (n=82), mean scores for all 30 PANSS items reflected absent-mild ratings at endpoint.
  • Logistic regression analysis found that remission (severity component only) was associated with a 97.1% probability of a 'not ill' rating on the Clinical Global Impressions-Severity.
  • These remission criteria identified patients who differed from the nonremitted population on symptoms of psychopathology, medication attitude, health status, and overall clinical status, supporting the clinical validity of the remission criteria.
  • [MeSH-minor] Adult. Female. Humans. Logistic Models. Male. Patients. Physicians. Psychiatric Status Rating Scales. Reproducibility of Results. Severity of Illness Index. Time Factors. Treatment Outcome


78. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Registries. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


79. Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G, GIMEMA Working Party on Chronic Myeloid Leukemia: Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica; 2008 Dec;93(12):1792-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
  • BACKGROUND: Imatinib mesylate is the first line treatment for chronic myeloid leukemia.
  • DESIGN AND METHODS: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis.
  • RESULTS: Ninety-two patients were enrolled (20 with lymphoid blast crisis and 72 with myeloid blast crisis).
  • Three of these patients are on imatinib treatment (1 in complete hematologic remission, 1 in partial cytogenetic response and 1 in complete cytogenetic remission).
  • Three patients are in complete remission after allogeneic stem cell transplantation.
  • CONCLUSIONS: Imatinib was effective and safe in the short-term treatment of chronic myeloid leukemia in blast crisis, but longer-term outcome was not significantly influenced (ClinicalTrials.gov identifier: NCT00514969).
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Benzamides. Blast Crisis. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Imatinib Mesylate. Male. Middle Aged. Survival Rate. Time Factors. Transplantation, Homologous. Treatment Outcome. Young Adult


80. d'Espiney Amaro C, Montalvão P, Henriques P, Magalhães M, Olias J: Nasopharyngeal carcinoma: our experience. Eur Arch Otorhinolaryngol; 2009 Jun;266(6):833-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety-five patients (60%) had remission.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Portugal / epidemiology. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2007 Apr;117(4):737-42 [17334261.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2627-33 [17473193.001]
  • [Cites] Radiother Oncol. 2003 Dec;69(3):227-36 [14644481.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):582-8 [9690553.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):474-81 [17234754.001]
  • [Cites] Radiother Oncol. 2006 Oct;81(1):39-46 [16965827.001]
  • [Cites] J Clin Virol. 2003 Oct;28(2):155-64 [12957185.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1183-91 [17315158.001]
  • [Cites] J Infect Dis. 2004 Jul 1;190(1):53-62 [15195243.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2002 Mar;111(3 Pt 1):210-6 [11913680.001]
  • [Cites] Head Neck. 1999 Jan;21(1):21-9 [9890347.001]
  • [Cites] Acta Otorrinolaringol Esp. 2007 May;58(5):191-7 [17498470.001]
  • [Cites] Cancer Sci. 2008 Jul;99(7):1311-8 [18498420.001]
  • [Cites] Am J Epidemiol. 2007 Feb 1;165(3):271-8 [17090616.001]
  • [Cites] Laryngoscope. 2007 Jan;117(1):142-6 [17202944.001]
  • [Cites] Head Neck. 2007 Feb;29(2):109-19 [17103409.001]
  • [Cites] Clin Radiol. 2007 Mar;62(3):195-203 [17293211.001]
  • [Cites] J Pathol. 1997 Oct;183(2):164-8 [9390028.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2162-6 [10070282.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):587-93 [8824359.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):622-7 [17149001.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2007 Apr;15(2):99-102 [17413410.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1007-15 [12176778.001]
  • [Cites] BMC Genomics. 2008 Jul 07;9:322 [18605998.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):29-35 [17060483.001]
  • [Cites] Acta Oncol. 2007;46(2):214-20 [17453372.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77 [17035381.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):130-7 [16979842.001]
  • [Cites] J Med Virol. 2006 Aug;78(8):1083-90 [16789009.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):675-9 [9833758.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1287-93 [16909425.001]
  • (PMID = 18830701.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


81. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


82. Serretta V, Morgia G, Altieri V, Di Lallo A, Ruggiero G, Salzano L, Battaglia M, Falsaperla M, Zito A, Sblendorio D, Melloni D, Allegro R, members of Gruppo Studi Tumori Urologici (GSTU) Foundation: A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. BJU Int; 2010 Jul;106(2):212-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Remission Induction / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20070299.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin
  • [Investigator] Carrieri G; Annese P; Gallo A; Motta M; Cindolo L; Selvaggi FP; Borruso L; Chincoli S; Saita A; Bartolotta A; Vaccarella G; Vacirca F; Cammarata C; Armenio A; Simone NS; Falvo F; Gentile M; Nicolosi D; Saracino A; Masala A; Napoli M; Bizzini A; D'Elia A; Aragona F; Gange E; Ricci Barbini V; Spampinato A; Curto G; Raguso G; Paola Q; Crimi A; Cicalese V
  •  go-up   go-down


83. Spacek J, Jilek P, Buchta V, Forstl M, Hronek M, Holeckova M: The serum levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidosis during attack, remission and in healthy controls. Mycoses; 2005 Nov;48(6):391-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The serum levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidosis during attack, remission and in healthy controls.
  • For statistical analysis were used the Student's t-tests (paired analysis for attack vs. remission; non-paired analysis for patient vs. control).
  • [MeSH-minor] Adolescent. Adult. Calcium / blood. Cohort Studies. Female. Humans. Iron / blood. Magnesium / blood. Matched-Pair Analysis. Middle Aged. Photometry. Recurrence. Remission, Spontaneous. Spectrophotometry, Atomic. Zinc / blood

  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16262875.001).
  • [ISSN] 0933-7407
  • [Journal-full-title] Mycoses
  • [ISO-abbreviation] Mycoses
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Metals; E1UOL152H7 / Iron; I38ZP9992A / Magnesium; J41CSQ7QDS / Zinc; SY7Q814VUP / Calcium
  •  go-up   go-down


84. Al-Amro A, Al-Rajhi N, Khafaga Y, Memon M, Al-Hebshi A, El-Enbabi A, El-Husseiny G, Radawi A, Belal A, Allam A, El-Sebaie M: Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):508-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete remission and partial remission were achieved in 87 patients (79%) and 23 patients (21%), respectively.
  • Acute Grade 3 and 4 reactions were also observed during chemoradiotherapy: anemia 1% and 0%, leukopenia 31% and 4%, nausea 35% and 0%, vomiting 26% and 2%, infection in 4% and 2%, mucositis in 49% and 0%, and skin reaction in 39% and 0%, respectively.
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Treatment Failure

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890594.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


85. Gérard L, Meignin V, Galicier L, Fieschi C, Leturque N, Piketty C, Fonquernie L, Agbalika F, Oksenhendler E: Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication. AIDS; 2009 Nov 13;23(17):2301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Outcome was similar in the two groups (complete remission, 64 versus 72.5%; P = 0.35 and 3-year survival, 46 versus 56%; P = 0.08).
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Female. Humans. Male. Middle Aged. Prospective Studies. RNA, Viral. Virus Replication


86. Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol; 2007 Aug 1;25(22):3350-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sustained remission (SR) off treatment at day 60 (primary end point) was achieved in 22 patients (92%).
  • From day 60 to day 365, one patient died with acute respiratory failure of undetermined origin, and four patients experienced relapse.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Polymerase Chain Reaction. Prospective Studies. Rituximab. Survival Analysis. Treatment Outcome


87. Krishna Sumanth M, Sharma VK, Khaitan BK, Kapoor A, Tejasvi T: Evaluation of oral methotrexate in the treatment of systemic sclerosis. Int J Dermatol; 2007 Feb;46(2):218-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Treatment of scleroderma is difficult and currently no treatment can induce complete remission of the disease.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Female. Humans. India. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17269983.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


88. Koscielny S, Gottschall R: [Diagnostic and therapeutic procedure for spontaneous emphysema of the neck and mediastinum]. HNO; 2005 Jul;53(7):645-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Cefuroxime / therapeutic use. Child, Preschool. Cough / complications. Diagnosis, Differential. Female. Follow-Up Studies. Foreign Bodies / complications. Foreign Bodies / diagnosis. Humans. Lifting. Male. Remission, Spontaneous. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Emphysema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Assoc Physicians India. 2002 Apr;50:613 [12164429.001]
  • [Cites] Gastroenterol Clin Biol. 1992;16(5):460-2 [1526399.001]
  • [Cites] Z Kardiol. 2003 Jul;92 (7):601-5 [12883845.001]
  • [Cites] J Obstet Gynaecol Res. 2002 Jun;28(3):172-5 [12214835.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 May;25(5):852-5 [15082293.001]
  • [Cites] Laryngoscope. 2002 May;112(5):791-5 [12150608.001]
  • [Cites] Chest. 2001 Jul;120(1):306-9 [11451856.001]
  • [Cites] Rev Med Liege. 2001 Jun;56(6):415-9 [11496720.001]
  • [Cites] Acta Otorrinolaringol Esp. 1995 Mar-Apr;46(2):152-6 [7598969.001]
  • [Cites] J Korean Med Sci. 1998 Apr;13(2):223-6 [9610628.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2003 Jun;9(3):188-91 [12875642.001]
  • [Cites] Pediatr Pulmonol. 2001 Jan;31(1):67-75 [11180677.001]
  • [Cites] Laryngoscope. 1985 Aug;95(8):939-41 [4021688.001]
  • [Cites] Laryngoscope. 1990 Sep;100(9):938-40 [2395401.001]
  • [Cites] Praxis (Bern 1994). 2002 Jul 3;91(27-28):1173-4 [12152359.001]
  • [Cites] Chest. 1992 Apr;101(4):1176 [1555448.001]
  • [Cites] An Med Interna. 2000 Dec;17(12):655-6 [11213583.001]
  • [Cites] Ugeskr Laeger. 1992 Jul 13;154(29):2004-7 [1509565.001]
  • [Cites] Postgrad Med. 1991 Jan;89(1):257-9 [1985316.001]
  • [Cites] Acta Chir Belg. 1997 Jun;97(3):145-7 [9224521.001]
  • [Cites] J Pediatr Surg. 2004 May;39(5):681-4 [15136999.001]
  • [Cites] Eur Respir J. 1995 Dec;8(12 ):2188-90 [8666117.001]
  • [Cites] Arch Bronconeumol. 2000 Apr;36(4):231 [10846612.001]
  • [Cites] Anaesthesia. 2001 Jan;56(1):93-4 [11167460.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1987 Oct;113(10 ):1111-2 [3620136.001]
  • [Cites] Respiration. 2000;67(4):408-11 [10940795.001]
  • [Cites] Anesth Analg. 2002 Oct;95(4):1123 [12351314.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1711-4 [12822604.001]
  • [Cites] Obstet Gynecol. 2001 Nov;98(5 Pt 2):904-6 [11704196.001]
  • [Cites] Probl Tuberk. 1998;(5):61-2 [9866405.001]
  • [Cites] Allergol Immunopathol (Madr). 2001 Jan-Feb;29(1):28-30 [11449532.001]
  • [Cites] J Emerg Med. 1993 Sep-Oct;11(5):525-9 [8308230.001]
  • [Cites] Intern Med. 2002 Apr;41(4):277-82 [11993787.001]
  • [Cites] Schweiz Rundsch Med Prax. 1991 Oct 29;80(44):1203-8 [1947555.001]
  • [Cites] Dtsch Med Wochenschr. 2002 Oct 25;127(43):2273-6 [12397542.001]
  • [Cites] Monaldi Arch Chest Dis. 1999 Aug;54(4):330-1 [10546476.001]
  • (PMID = 15549212.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] O1R9FJ93ED / Cefuroxime
  •  go-up   go-down


89. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S: Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia; 2008 Feb;22(2):258-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 'Response' was engraftment and remission (CR) on day +30.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Antigens, CD. Antigens, Differentiation, Myelomonocytic. Disease-Free Survival. Female. Graft Survival. Humans. Male. Melphalan / administration & dosage. Middle Aged. Remission Induction. Sialic Acid Binding Ig-like Lectin 3. Survival Rate. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17989720.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


90. Coronel-Pérez IM, Rodríguez-Rey EM, Pérez-Bernal AM, Camacho FM: [Epidemiology of pemphigus in the Hospital Universitario Virgen Macarena, Seville, Spain, 2005-2006]. Actas Dermosifiliogr; 2009 Mar;100(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete remission was induced in 8.68 % of patients and partial remission in 91.32 %.
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / adverse effects. Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Azathioprine / administration & dosage. Azathioprine / therapeutic use. Cushing Syndrome / chemically induced. Drug Therapy, Combination. Female. Humans. Hypertension / chemically induced. Infection / epidemiology. Infection / etiology. Male. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Mycophenolic Acid / administration & dosage. Mycophenolic Acid / analogs & derivatives. Mycophenolic Acid / therapeutic use. Retrospective Studies. Spain / epidemiology

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445876.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunosuppressive Agents; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid; MRK240IY2L / Azathioprine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


91. Gondim JA, Ferraz T, Mota I, Studart D, Almeida JP, Gomes E, Schops M: Outcome of surgical intrasellar growth hormone tumor performed by a pituitary specialist surgeon in a developing country. Surg Neurol; 2009 Jul;72(1):15-9; discussion 19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: All 33 patients had intrasellar adenoma, 84.84% of patients achieved remission by surgery.
  • CONCLUSION: Our patients, with intrasellar GH tumor, operated by a pituitary specialist neurosurgeon had remission rates approaching those obtained by most specialized neurosurgical centers worldwide.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Brazil. Cost-Benefit Analysis. Developing Countries. Female. Humans. Male. Middle Aged. National Health Programs / economics. Octreotide / therapeutic use. Outcome Assessment (Health Care) / methods. Reoperation / statistics & numerical data. Retrospective Studies. Specialization / economics. Specialization / statistics & numerical data. Treatment Failure. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440607.001).
  • [ISSN] 1879-3339
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


92. Han Y, Xue Y, Zhang J, Wu Y, Pan J, Wang Y, Shen J, Dai H, Bai S: Translocation (14;14)(q11;q32) with simultaneous involvement of the IGH and CEBPE genes in B-lineage acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2008 Dec;187(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (14;14)(q11;q32) with simultaneous involvement of the IGH and CEBPE genes in B-lineage acute lymphoblastic leukemia.
  • However, t(14;14)(q11;q32) is an exceedingly rare phenomenon in B-lineage acute lymphoblastic leukemia (B-ALL).
  • After chemotherapy, the patient achieved complete remission (CR).
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / genetics. Chromosomes, Human, Pair 14 / genetics. Immunoglobulin Heavy Chains / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / genetics. Daunorubicin / therapeutic use. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Prednisone / therapeutic use. Trisomy. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027493.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCAAT-Enhancer-Binding Proteins; 0 / Immunoglobulin Heavy Chains; 142805-41-2 / CEBPE protein, human; 5J49Q6B70F / Vincristine; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; VDP protocol
  •  go-up   go-down


93. Gutierrez-Aguirre CH, Gomez-Almaguer D, Cantu-Rodríguez OG, Gonzalez-Llano O, Jaime-Perez JC, Herena-Perez S, Manzano CA, Estrada-Gomez R, Gonzalez-Carrillo ML, Ruiz-Argüelles GJ: Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplant; 2007 Sep;40(6):535-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study.
  • Ten patients (23%) developed acute GVHD, whereas eight patients (18.6%) developed chronic GVHD.
  • These results are inferior to those obtained using the same allografting method in other leukemias, probably as a consequence of poor susceptibility to the graft-versus-leukemia effect of the ALL cells beyond first remission as compared with other hematological malignancies.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Granulocytes / cytology. Humans. Infant. Leukocyte Count. Male. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Survival Rate. Transplantation, Homologous


94. Koenecke C, Hofmann M, Bolte O, Gielow P, Dammann E, Stadler M, Franzke A, Boerner AR, Eder M, Ganser A, Knapp W, Hertenstein B: Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia. Int J Hematol; 2008 May;87(4):414-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia.
  • Between July 2000 and June 2003 a total of 21 patients with high-risk acute myeloid leukemia (AML; n = 14), AML after myelodysplastic syndrome (MDS; n = 6) or advanced MDS (n = 1) were treated with an 188-Re labelled anti-CD66 antibody in the conditioning regimen for allogeneic stem cell transplantation.
  • Nine patients are still alive and in ongoing complete hematological remission.
  • The combination of RIT with chemotherapeutic conditioning seems to be a therapy with an acceptable risk of treatment related morbidity and mortality as well as occurrence of severe acute GvHD.
  • [MeSH-major] Antibodies / therapeutic use. Antigens, CD / immunology. Cell Adhesion Molecules / immunology. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / radiotherapy. Radioimmunotherapy. Rhenium. Stem Cell Transplantation
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Radioisotopes. Recurrence. Risk Factors. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2003 Sep;32(6):549-56 [12953125.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4):520-30 [12939721.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):604-13 [16098076.001]
  • [Cites] Eur J Nucl Med. 1989;15(9):605-8 [2598956.001]
  • [Cites] Lancet. 1989 Feb 11;1(8633):299-301 [2563458.001]
  • [Cites] Eur J Nucl Med. 1999 Oct;26(10):1265-73 [10541824.001]
  • [Cites] Lancet. 1995 Aug 5;346(8971):336-40 [7623531.001]
  • [Cites] J Nucl Med. 2004 Jun;45(6):1059-64 [15181141.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1660-5 [2015394.001]
  • [Cites] Cancer. 1997 Dec 15;80(12 Suppl):2591-610 [9406714.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(10):807-16 [12058230.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):47-50 [1967149.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):807-15 [11504076.001]
  • [Cites] Oncology (Williston Park). 2004 May;18(5):623-30; discussion 633-4, 637-8, 640 [15209190.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1867-71 [2224134.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):316-21 [12042706.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(3):139-44 [11939603.001]
  • [Cites] Blood. 2004 Jun 15;103(12 ):4429-31 [15016644.001]
  • [Cites] Acta Radiol Ther Phys Biol. 1964 Jun;2:169-78 [14174628.001]
  • [Cites] Strahlenther Onkol. 2003 Oct;179(10):702-7 [14566479.001]
  • [Cites] J Nucl Med. 2000 Mar;41(3):531-7 [10716329.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1122-31 [7849300.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3599-604 [9808553.001]
  • [Cites] J Nucl Med. 1996 Mar;37(3):538-46 [8772664.001]
  • [Cites] Bone Marrow Transplant. 1997 Dec;20(12):1069-74 [9466280.001]
  • [Cites] Blood. 2001 Aug 1;98(3):565-72 [11468151.001]
  • [Cites] Cancer Control. 2002 Mar-Apr;9(2):106-13 [11965231.001]
  • [Cites] Eur J Nucl Med. 1994 Oct;21(10):1151-65 [7828627.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1469-79 [15084620.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2270-1 [11902136.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1562-8 [3049951.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1251-61 [12830326.001]
  • (PMID = 18415659.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Radioisotopes; 7440-15-5 / Rhenium
  •  go-up   go-down


95. Mastrantuono D, Martorano D, Verna V, Mancini A, Faletti C: Osteoid osteoma: our experience using radio-frequency (RF) treatment. Radiol Med; 2005 Mar;109(3):220-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical results indicate a 100% success rate with complete remission of symptoms and no relapses having been reported at the time of writing for those patients who have arrived at the two year follow up (4 out of 21).
  • [MeSH-minor] Adolescent. Adult. Bone Density. Early Ambulation. Female. Femoral Neoplasms / surgery. Follow-Up Studies. Foot Bones / surgery. Humans. Humerus / surgery. Male. Minimally Invasive Surgical Procedures. Pelvic Bones / surgery. Radiography, Interventional. Remission Induction. Tibia / surgery. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15775890.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


96. Agarwal M, Shenjere P, Blewitt RW, Hall G, Sloan P, Pigadas N, Banerjee SS: CD30-positive T-cell lymphoproliferative disorder of the oral mucosa--an indolent lesion: report of 4 cases. Int J Surg Pathol; 2008 Jul;16(3):286-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All biopsies showed a dense lymphoid infiltrate composed of CD30+ atypical T cells with a polymorphous infiltrate in the background, which included eosinophils.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Rearrangement, T-Lymphocyte / genetics. Humans. Immunohistochemistry. Male. Middle Aged. Remission, Spontaneous. Tongue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387994.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


97. Melikian AL, Kaplanskaia IB, Korneva EP, Frank GA: [Castleman's disease]. Ter Arkh; 2005;77(7):48-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the patients with hyalinovascular KD variant were treated surgically (enlarged lymph nodes were removed) and achieved remission.
  • [MeSH-minor] Adolescent. Adult. Anemia, Hemolytic, Autoimmune / complications. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymph Nodes / pathology. Male. Middle Aged. Plasma Cells / pathology

  • Genetic Alliance. consumer health - Castleman's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116909.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 19
  •  go-up   go-down


98. Yamauchi T, Mori Y, Miyamoto T, Kamezaki K, Aoki T, Yamamoto A, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Teshima T, Akashi K: Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia. Int J Hematol; 2009 Oct;90(3):416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia.
  • Gemtuzumab ozogamicin (GO) is an effective molecular-targeted agent for CD33-positive acute myelogenous leukemia (AML) patients who are resistant to conventional chemotherapy.
  • Notably, one patient who responded to GO survived for 6 months after UCBT in remission with excellent performance status, while the remaining cases relapsed early.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Cord Blood Stem Cell Transplantation. Leukemia, Myeloid, Acute / drug therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Combined Modality Therapy. Fatal Outcome. Female. Humans. Male. Middle Aged. Recurrence


99. Wedekind D, Preiss B, Cohrs S, Ruether E, Huether G, Adler L: Relationship between nocturnal urinary cortisol excretion and symptom severity in subgroups of patients with depressive episodes. Neuropsychobiology; 2007;56(2-3):119-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: The observation that the basal HPA activity remains elevated even after remission of symptoms in patients with psychotic depression supports the concept that a dysfunctional regulation of the HPA system is possibly a trait- rather than a state-related feature.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18182828.001).
  • [ISSN] 1423-0224
  • [Journal-full-title] Neuropsychobiology
  • [ISO-abbreviation] Neuropsychobiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


100. Gao ZR, An R, Zhang YX, Biersack HJ: [Targeted radionuclide therapy for patients with metastatic medullary thyroid carcinoma]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):621-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After three to five sessions of treatment, three patients with partial remission and six with stable disease were observed.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Follow-Up Studies. Humans. Indium Radioisotopes. Male. Middle Aged. Pentetic Acid / analogs & derivatives. Positron-Emission Tomography. Remission Induction. Thyroid Gland / pathology. Thyroid Gland / radiation effects. Thyroid Gland / radionuclide imaging. Thyroid Hormones / metabolism. Treatment Outcome. Yttrium Radioisotopes / therapeutic use

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236560.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / 111In-octreotide, DTPA(0)-; 0 / 90Y-octreotide, DOTA-Tyr(3)-; 0 / Antineoplastic Agents; 0 / Indium Radioisotopes; 0 / Thyroid Hormones; 0 / Yttrium Radioisotopes; 35MRW7B4AD / 3-Iodobenzylguanidine; 7A314HQM0I / Pentetic Acid; RWM8CCW8GP / Octreotide
  •  go-up   go-down






Advertisement